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ABSTRACT: Mycobacterium abscessus (Mab) is a rapidly growing species of multidrug-resistant nontuberculous mycobacteria
that has emerged as a growing threat to individuals with cystic ﬁbrosis and other pre-existing chronic lung diseases. Mab
pulmonary infections are diﬃcult, or sometimes impossible, to treat and result in accelerated lung function decline and
premature death. There is therefore an urgent need to develop novel antibiotics with improved eﬃcacy. tRNA (m1G37)
methyltransferase (TrmD) is a promising target for novel antibiotics. It is essential in Mab and other mycobacteria, improving
reading frame maintenance on the ribosome to prevent frameshift errors. In this work, a fragment-based approach was
employed with the merging of two fragments bound to the active site, followed by structure-guided elaboration to design potent
nanomolar inhibitors against Mab TrmD. Several of these compounds exhibit promising activity against mycobacterial species,
including Mycobacterium tuberculosis and Mycobacterium leprae in addition to Mab, supporting the use of TrmD as a target for
the development of antimycobacterial compounds.
■ INTRODUCTION
Mycobacterium abscessus (Mab) is an opportunistic human
pathogen responsible for a wide range of lung, skin, and soft
tissue infections. Although acquisition was thought to occur
through environmental exposure (from soil and/or water), it has
become apparent that indirect person-to-person transmission
may be an important route of infection in cystic ﬁbrosis (CF)
patients (via fomite or long-lived infectious aerosol spread).1,2 In
CF patients, Mab infection results in accelerated inﬂammatory
lung damage and impaired quality and quantity of life.3−5Mab is
challenging to treat because of its unique combination of drug-
modifying enzymes, high number of eﬄux pumps, and genetic
polymorphism of target genes, in addition to its complex and
impermeable multilayered cell envelope. As a result, Mab
possesses both intrinsic and acquired resistance to currently
available antibiotics6 and is therefore currently diﬃcult or
sometimes impossible to treat.5 Consequently, there is an acute
need for novel antibiotics with improved eﬃcacy against Mab
infection.
tRNA (m1G37) methyltransferase (TrmD), a member of the
SpoU-TrmD (SPOUT) RNA methyltransferase family, cata-
lyzes the transfer of a methyl group from S-adenosyl methionine
(SAM) to the N1 position of guanosine 37 in bacterial tRNA
when preceded by another guanosine in the sequence.7 The
addition of this marker immediately adjacent to the anticodon
acts to improve reading frame maintenance on the ribosome,
preventing frameshift errors that would result in truncated and
inactive peptides.8 TrmD has been shown to be essential for
growth in a range of bacterial species from Staphylococcus aureus
and Pseudomonas aeruginosa to mycobacteria, including
Mycobacterium tuberculosis (Mtb) and Mab.9−12
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The X-ray crystal structure of Mab TrmD shows a fold
consistent with that of previously described TrmD en-
zymes,13−15 with a homodimeric structure exhibiting deep
trefoil knots for SAM binding in two symmetry-related sites.
These sites are formed by contributions from the N- and C-
terminal domains of alternate subunits, which are separated by
catalytically relevant interdomain linkers that show organization
upon tRNA binding.16 The analogue of TrmD in archaea and
eukaryotes, Trm5, is structurally distinct with a diﬀering SAM
binding mode.17 This reduces the chance of an inhibitor ofMab
TrmD binding oﬀ-site in the human host, making this essential
enzyme an attractive target for drug development.
The attractiveness of TrmD as a target is reﬂected in the
recent application of a high-throughput screen against TrmD
from P. aeruginosa to identify low-micromolar inhibitors.18
However, there are currently on-going eﬀorts to validate the in
vivo mechanism of these compounds before they are further
developed as antibiotics. Structure-driven fragment-based
methods provide an alternative methodology for the eﬃcient
design of potent inhibitors from low-molecular weight starting
points and are now ﬁrmly established in both academia and
industry.19 A fragment-based approach was used in a prior study
against Haemophilus inﬂuenzae TrmD to develop selective
inhibitors that ordered the interdomain linker in a similar
manner to tRNA.20 Disappointingly, in general, these
compounds only displayed weak activity when screened against
a range of Gram-positive and Gram-negative pathogens,
including eﬄux mutant strains of Escherichia coli and H.
inﬂuenzae. In this work, a fragment-based approach was
employed to design potent inhibitors against Mab TrmD that
show growth inhibition across a range of pathogenic
mycobacteria.
■ RESULTS AND DISCUSSION
A fragment library of 960 fragments was screened against TrmD
using diﬀerential scanning ﬂuorimetry (DSF) as a primary
screen. This resulted in 53 hits with a thermal shift cut-oﬀ value
of 3 standard deviations from the negative control. These hits
were then carried forward for soaking experiments using X-ray
crystallography. Of these hits, density was observed for 27
fragments, all of which were shown to bind at the SAM binding
pocket ofMabTrmD. The remaining 26 fragments did not show
any electron density.12 This work herein describes the use of
fragment-growing and merging strategies on fragment hits to
develop novel compounds to inhibit Mab TrmD. Using the
fragment-merging strategy, compounds have been developed
that aﬀord up to a 4-order of magnitude improvement in aﬃnity
againstMab TrmD, combined with inhibition ofMab growth in
vitro and in a human macrophage infection model. A number of
these key compounds display potent inhibition ofMtb growth in
vitro, while one of the lead molecules also exhibits growth
inhibition of intracellular Mycobacterium leprae.12
Fragment-Growing Strategy. The SAM co-factor has
been shown by X-ray crystallography to bind to Mab TrmD
simultaneously in the two symmetry-related active sites, with the
adenine ring “anchoring” the molecule in place through
hydrogen bonds to the backbone amides of residues Ile133,
Gly134, Tyr136, and Leu138 (Figure 1a).12 This is formed from
the loop of Val131 to Leu138, bordered behind and above by
Pro83 and Pro85, and below by Ile133, Tyr136, Leu138, and
Ala144, encompassing the “adenine binding pocket”. Fragment
hit 1 (Kd 89 μM, LE 0.55, Table 1) was observed by X-ray
crystallography to occupy the adenine binding pocket, with the
pyrazole ring hydrogen bonding to the backbone amides of
Gly134 and Ile133, and the carbonyl oxygen engaging the
backbone amide of Leu138 (Figure 1b). This highly ligand-
eﬃcient fragment was chosen as a starting point for a fragment-
growing strategy (Table 1). DSF screening was used as a ﬁrst line
screen with the elaborated compounds as a guide to prioritize
compounds for isothermal titration calorimetry (ITC). The
ester group of 1 was shown to be resistant to replacement, with
the amide analogue 2 giving a thermal shift below +0.5 °C at 5
Figure 1. (a) X-ray crystal structures of Mab TrmD in complex with SAM (PDB code 6NW6),12 illustrating both the whole dimer (individual
protomers in blue/gray) with the positions of the active sites highlighted and one of the active sites in detail, and Mab TrmD in complex with (b) 1
(PDB code 6QOS)12 and (c) 7 (PDB code 6QRE), illustrating one of the active sites.
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mM (+4.0 °C for 1) by DSF. From the X-ray crystal structure,
the ethyl chain of 1 extends into the region occupied by the
ribose portion of SAM, the “ribose binding pocket” (Figure
1a,b). This was used as a vector for a fragment-growing strategy.
The phenyl ring introduced in 3 (Kd 33 μM, LE 0.41) was shown
by X-ray crystallography to occupy the ribose-binding pocket
(Figure S1a). This induced amovement in Tyr111 (2.5−5.1 Å at
C-α depending on the active site), similar to that shown in the
SAM-bound Mab TrmD X-ray crystal structure. From the
synthesized analogues of 3 with varying substituents, 7 (Kd 14
μM, LE 0.39) demonstrated a ligand-eﬃcient improvement in
binding aﬃnity. The X-ray crystal structures of 7- and 3-bound
Mab TrmD both showed evidence of a second ligand molecule
in the active site bound to the backbone amide nitrogen of
Glu180 through its carbonyl oxygen (Figures 1c and S1a).
Compound 7 was used as the basis for further derivatives
(Table 2), initially from the use of the 3-methoxy group as a
vector for growth (see Figure S1). The use of aromatic rings in 9
(ΔTm +2.5 °C) and 11 (ΔTm +3.0 °C), an ester group in 8 (Kd
10 μM, LE 0.32) or chain extension in 10 (Kd 11 μM, LE 0.38)
did not result in either a signiﬁcant improvement in binding
aﬃnity or, when this was not determinable by ITC, an increase
in thermal shift. The observation of a second ligand molecule for
7 in the active site was exploited for a fragment linking approach,
with the attachment of a molecule of 1 to the scaﬀold of 7
through a propynyl linker in 12 (Kd 4.6 μM, LE 0.24); however,
while an improved binding aﬃnity was achieved, the ligand
eﬃciency was adversely aﬀected. The 5-position of the phenyl
ring of 7 was also utilized as a vector for growth for the insertion
of ring systems into the volume bordered by residues Glu112,
Val137, Arg154, and Glu180. However, while the added
pyrrolidinyl and pyridyl groups were tolerated in 13 (Kd 10
μM, LE 0.31) and 14 (Kd 6.7 μM, LE 0.31), a signiﬁcant
improvement in aﬃnity was again not achieved, including with
the addition of a methylene linker in 15 (Kd 12 μM, LE 0.28).
Protein X-ray crystallography showed that the added groups in 8
and 14 did reach the desired regions of the active site in Mab
TrmD (Figure S1b,c); however, attempts to improve the aﬃnity
using the stated strategies proved challenging. The lack of
increase in aﬃnity and the liability of the ester functional group
in these compounds pointed to the need to develop an
alternative strategy to target Mab TrmD.
Fragment-Merging Strategy. In a similar way to
compound 1 (Kd 89 μM, LE 0.55, Table 2), the aminopyrazole
ring system of fragment hit 16 (Kd 170 μM, LE 0.37) occupied
the adenine binding pocket, with the pyrazole ring hydrogen
bonding to the backbone amides of Tyr136 and Leu138 and the
amino group engaging Gly134 and the alcohol side chain of
Ser132 (Figure 2a). In contrast, the 4-methoxyphenyl ring of 16
extended into the ribose binding pocket. The methoxy group
showed no direct interactions with the surrounding residues;
however, the corresponding phenyl (17) and 4-tolyl (18)
analogues lacking the methoxy group aﬀorded relatively low
ΔTm values (1.4−1.5 °C). The methoxy group of 16 was also
shown to possess a preference for the 4-position of the phenyl
ring, with the 3-methoxyphenyl analogue 19 providing a
negative thermal shift (Table 3). The ribose binding pocket
was shown to be occupied by the indole ring of fragment hit 20
(Kd 260 μM, LE 0.41), where the indole nitrogen indirectly
interacts with the backbone carbonyl of Leu138 through a water
molecule. The 6-boronic acid group of 20 partially extends into
the adenine binding pocket, engaging the backbone amides of
residues Tyr136 and Leu138 through hydrogen bonds, as well as
two water molecules that occupy the remaining space in the
pocket, interacting with the backbone amides of Val131, Ile133,
and Gly134 in addition to the side chain of Ser132 (Figure 2b).
The isosteric replacement of the boronic acid group with a
carboxylic acid, as shown in fragment 21, was shown to not be
tolerated, with no ΔTm observed. Further, examination of the
structure with 5-boronic acid isomer 22 bound using X-ray
crystallography showed the indole ring “ﬂipping” tomaintain the
Table 1. Change in the Melting Temperatures (ΔTm),
Aﬃnities (Kd), and Ligand Eﬃciencies (LE) of Fragment Hit
1 and Compounds 2−7
compound ΔTma (°C) R Kd (μM) LEb
1 +0.4c 89 ± 4 0.55
2 NDd ND
3 +3.1 H 33 ± 2 0.41
4 +0.4 4-NO2 ND
5 +0.9 4-CO2Me ND
6 +2.8 3-CN 30 ± 1 0.36
7 +3.5 3-OMe 14 ± 1 0.39
a100 μM ligand and 10 μM Mab TrmD. bkcal mol−1 per heavy atom.
cDetermined to be +4.0 °C with 5 mM ligand and 10 μM Mab
TrmD.12 dDetermined to be +0.4 °C with 5 mM ligand and 10 μM
Mab TrmD.
Table 2. Change in the Melting Temperatures (ΔTm),
Aﬃnities (Kd), and Ligand Eﬃciencies (LE) of Compounds
8−15
a100 μM ligand and 10 μM Mab TrmD. bkcal mol−1 per heavy atom.
cNot determined due to solubility.
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hydrogen bonding interactions of the boronic acid, with the
indole nitrogen interacting with an extensive hydrogen-bonded
water network in the rear of the active site (Figure S2a). Even
though the boronic acid of 22 was shown to form the same
hydrogen-bonding water network in the adenine binding pocket
as 20, it gave a lower ΔTm (Table 3). The overlap of the
respective 4-methoxyphenyl and indole ring systems of 16 and
20 (Figure 2c), and their spanning of the adenine and ribose
binding pockets, oﬀers the possibility of a fragment-merging
strategy. This was explored successfully with 23 (Kd 110 μM, LE
0.36), providing a new aminopyrazole-indole scaﬀold with both
improved aﬃnity and prospects for further elaboration relative
to the parent fragments (Figure 2d). Compound 23 was shown
by X-ray crystallography to maintain the hydrogen-bonding
interactions of the original fragment 16, which remained
unaﬀected throughout all subsequent additions to the scaﬀold,
with the indole nitrogen providing a vector for elaboration that
the fragment hit 16 lacked.
Elaboration of Compound 23. Elaboration of 23 was
initially carried out from the indole nitrogen with the
introduction of a 4-methoxybenzyl group in 24a (Kd 59 μM,
LE 0.24) (Table 4). While the gain in aﬃnity was less than
desired, the added group reached the portion of the active site
occupied by the methionine moiety of SAM deﬁned by Pro85,
Glu112, Val137, Arg154, and Glu180 (Figure 3a). The synthesis
of the 3-methoxybenzyl 24b (Kd 13 μM, LE 0.28) and benzyl
24c (Kd 19 μM, LE 0.29) derivatives demonstrated improved
aﬃnities (GE 0.14 and 0.15, respectively). While the 2-
benzamide 24e gave a lower ΔTm of +1.4 °C, further
improvements in aﬃnity were realized relative to 24c with the
synthesis of the 2-cyanobenzyl 24d (Kd 12 μM, LE 0.28) and 2-
picolyl 24f (Kd 12 μM, LE 0.30) analogues. Attention was also
focused on elaboration from the 4-position of the pyrazole ring
of 23. This vector was shown by X-ray crystallography to face a
narrow and elongated pocket formed by Pro83, Thr84, Val131,
Ser132, Ile133, and Ala144 (Figure 2d). The addition of a nitrile
group in 25 (Kd 5.0 μM, LE 0.43) aﬀorded a jump in aﬃnity
from 23 (Kd 110 μM, LE 0.36), with the added functionality
highly group eﬃcient (GE 0.91). An X-ray crystal structure of 25
bound to TrmD showed that the nitrile extended into the
pocket, engaging the backbone amides of Thr84 and Ile133, with
no major changes in the ligand binding orientation or
conformation of neighboring residues (Figure 3e). The nitrile
was subsequently incorporated into 24f to aﬀord 26f (Kd 0.50
μM, LE 0.36), with the added nitrile functional group aﬀording a
similar jump in aﬃnity as in 25 (GE 0.95 and 0.91 respectively).
Following the development of 26f, the corresponding 3-
pyridyl isomer 26g (Kd 0.18 μM, LE 0.38, Table 5) aﬀorded a
greater than 2-fold improvement in binding aﬃnity without
additional interactions being observed in the X-ray crystal
structure of ligand-bound Mab TrmD (Figures 3f and 4a). The
late stage functionalization of 26g through addition of a chlorine
atom on the 3-position of its indole ring in 27g (Kd 8.5 μM, LE
0.28) was not tolerated (Table 5). While this modiﬁcation of
26g did not result in a signiﬁcant shift in the indole ring, one of
the ordered water molecules in the rear of the active site bound
Figure 2.X-ray crystal structures ofMabTrmD in complex with (a) 16 (PDB code 6QOT), (b) 20 (PDB code 6QOU), (c) 16 and 20 (overlay of PDB
code 6QOT and PDB code 6QOU), and (d) 23 (PDB code 6QQS), illustrating one of the active sites.12
Table 3. Change in the Melting Temperatures (ΔTm),
Aﬃnities (Kd), and Ligand Eﬃciencies (LE) of FragmentHits
16 and 20, Their Structural Analogues 17−19 and 21−22,
and Compound 23
compound R1 R2 ΔTma (°C) Kd (μM) LEb
16c 4-OMe +3.0 170 ± 10 0.37
17 H +1.5 ND
18 4-Me +1.4 ND
19 3-OMe −0.5 ND
20c 6-B(OH)2 +4.0 260 ± 20 0.41
21 6-CO2H −0.6 ND
22 5-B(OH)2 +1.3 ND
23d +4.8e 110 ± 10 0.36
a5 mM ligand and 10 μM Mab TrmD. bkcal mol−1 per heavy atom.
cΔTm, Kd and LE previously reported.12 dKd and LE previously
reported.12 eDetermined to be +1.1 °C with 100 μM ligand and 10
μM Mab TrmD.
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to Pro83 was displaced (Figure 4b). 2-Hydroxypyridyl/
pyridone derivatives of 26g, 26j (Kd 3.2 μM, LE 0.30), and
26k (Kd 1.3 μM, LE 0.32) were synthesized to engage
neighboring residues Arg154 and Glu180, respectively, through
the added oxygen atoms. While the X-ray crystal structure of
Mab TrmD with 26j bound did show evidence of a hydrogen
bond between the added oxygen atom of the ligand and Arg154
(Figure 4c), neither derivative possessed an improved binding
aﬃnity. In contrast, the exploration of the alternative 4-pyridyl
isomer 26l (Kd 0.12 μM, LE 0.39) resulted in a 4-fold decrease of
Kd value relative to 26f, with the nitrogen atom of its pyridyl ring
lying 2.9 Å from the carboxylate group of Glu180 (Figure 4d).
Modiﬁcation of the pyridyl ring of 26l to the corresponding 4-
quinolyl ring system in 26m aﬀorded a signiﬁcant thermal shift
(ΔTm +10.3 °C at 100 μM), suggesting that the bicyclic ring was
tolerated (Table 5). However, this modiﬁcation adversely
aﬀected solubility, precluding the determination of binding
aﬃnity by ITC at the desired concentrations. The replacement
of the pyridyl ring with more soluble saturated alternatives
resulted in the development of racemic compounds N-methyl
piperidin-2-yl 26n (Kd 0.59 μM, LE 0.34) and N-methyl
piperidin-3-yl 26o (Kd 0.36 μM, LE 0.35), whose ITC isotherms
could be ﬁtted by a one-site binding model (Figures S7d and
S8a). However, racemic mixtures can aﬀord deceptively simple
isotherms under certain circumstances, such as when the
enthalpies of binding of the individual enantiomers are
equivalent, with the curve mimicking the Kd of the weaker
component.21 Hence, a reverse ITC titration was also performed
for 26o. This aﬀorded a simple curve that could be ﬁtted by
similar parameters to the forward titration (Figure S8b),
implying that the enantiomers of 26o are equipotent. The X-
ray crystal structure of 26n showed that the nitrogen atom of its
piperidinyl ring interacts with the backbone carbonyl of Tyr111
(Figure S2c), while that of 26o formed electrostatic interactions
with either of Glu112 or Glu180 depending on the active site
(Figure 4e,f).
The targeting of Glu112 and Glu180 through electrostatic
interactions with saturated heterocyclic ring systems was
continued, with the pyridyl ring of 26f providing a good starting
point for the presentation of amines at the top of the active site
(Table 6). The implementation of a similar strategy against H.
inﬂuenzae TrmD with engagement of the catalytic residue
Asp169 resulted in improved inhibition and the ordering of the
interdomain linker.20 The addition of a pyrrolidinyl ring through
amethylene linker to 26f in 28 (Kd 92 nM, LE 0.32) showed that
the strategy was applicable to this lead series. Modiﬁcation of the
scaﬀold through replacement of the pyridyl ring of 28 with a
phenyl ring in 29a (Kd 27 nM, LE 0.34) was beneﬁcial to the
binding aﬃnity, in contrast to the diﬀerence in aﬃnities between
the phenyl and pyridyl derivatives 24c (Kd 19 μM, LE 0.29) and
24f (Kd 12 μM, LE 0.30). The X-ray crystal structure of Mab
TrmD in complex with 29a showed the pyrrolidinyl ring
occupying the binding sites in two conformations, thereby
interacting with the carboxylates of either Glu112 or Glu180,
while Asp169 and the rest of the interdomain linker remained
unstructured (Figure 5a,b). Replacement of the nitrile group on
the 4-position of the pyrazole ring of 29a was also explored
through the methyl-substituted alternative 30a (Kd 2.0 μM, LE
0.27), which showed a higher binding aﬃnity than the
unsubstituted derivative 31a (Kd 0.49 μM, LE 0.31). Derivatives
of 29a with alternative substituents in place of its pyrrolidinyl
ring were trialed, including 29b (Kd 70 nM, LE 0.31) whose
piperidinyl ring was shown to interact with Glu112 in preference
to Glu180 (Figure 5c). The use of a morpholinyl ring resulted in
a signiﬁcant attenuation of binding aﬃnity in 29c (Kd 0.19 μM,
LE 0.30), possibly because of the impact of reduced basicity of
Table 4. Change in the Melting Temperatures (ΔTm), Aﬃnities (Kd), and Eﬃciency Metrics of Compounds 24a−f, 25, 26c, and
26f
a100 μM ligand and 10 μM Mab TrmD. bkcal mol−1 per heavy atom. cKd and LE previously reported.
12 dNot determined due to solubility.
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the morpholinyl nitrogen on its interactions with Glu112 and
Glu180. Protein X-ray crystallography showed that compound
29c adopted a similar binding pose as 29b, but with the
morpholinyl ring rotated and orienting its oxygen atom toward
Pro57 (Figure 5d). In contrast to 29c, the N-methyl piperazinyl
ring of 29d (Kd 73 nM, LE 0.30) was oriented away fromGlu112
with its methyl group extending further into the pocket deﬁned
by the loop from Ala176 to Glu180 (Figure 5e). The methyl
substituent on the piperazinyl ring of 29d was expanded to an
isopropyl group in 29e (Kd 0.10 μM, LE 0.28), whose electron
density maps suggest two alternative binding poses with the
isopropyl group oriented toward either Glu112 or the loop from
Ala176 to Glu180 at the top of the active site (Figure 5f).
Native Mass Spectrometry. Native mass spectrometry
(native MS) was used to investigate the structure and
interactions of Mab TrmD. The protein alone presented as the
dimer with an observed mass of 53 187 Da, centered around the
15+ charge state (Figure 6). The observedmass is slightly higher
than the theoretical mass of 52 520 Da because of the presence
of solvent and buﬀer molecules that remain weakly bound to the
protein under the soft ionization conditions employed.22 In the
presence of 5% dimethylsulfoxide (DMSO), the native mass
spectrum of Mab TrmD shifted to a lower charge state
distribution (Figure 6). This is consistent with previous studies
on the eﬀect of DMSO on protein charging in electrospray
ionization (ESI).23,24
Native MS was used to study the interaction between the
small molecules and Mab TrmD. A titration experiment
performed with 24c revealed increasing occupancy of the
Figure 3. X-ray crystal structures of Mab TrmD in complex with (a) 24a (PDB code 6QQT), (b) 24b (PDB code 6QRC), (c) 24c (PDB code
6QQW), (d) 24f (PDB code 6QQX),12 (e) 25 (PDB code 6QQU), and (f) 26f (PDB code 6QQY),12 illustrating one of the active sites.
Table 5. Change in the Melting Temperatures (ΔTm),
Aﬃnities (Kd), and Eﬃciency Metrics of Compounds 26g,
26j−o, and 27g
a100 μM ligand and 10 μM Mab TrmD. bkcal mol−1 per heavy atom.
cNot determined due to solubility.
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protein as the concentration of the ligand was increased (Figure
6). At 20 μM of Mab TrmD and 12.5 μM of 24c (with 5%
DMSO), a single molecule of the ligand could be observed to
bind to the 13+ charge state of the protein, although themajority
of that charge state remained unbound. At 25 μM of 24c, both
singly and doubly bound Mab TrmD could be detected at the
13+ charge state. The proportion of doubly bound Mab TrmD
increased at 50 μMof 24c, while at 100 μM, the 13+ charge state
of the protein was entirely doubly bound. A similar trend could
be observed for the 14+ charge state, except that the degree of
occupancy of the protein was lower at each concentration of 24c
due to the greater Coulombic repulsion experienced by the
protein-ligand complexes at 14+ compared to at 13+. The lack of
triply boundMab TrmD observed even at excess concentrations
of 24c suggests that little, if any, of the small molecule bound
non-speciﬁcally to the protein dimer.
Compounds 26c and 29a were also screened against Mab
TrmD using native MS at a ligand concentration of 100 μM
(Figure 6). Interestingly, despite its tight binding aﬃnity for
Mab TrmD as measured by ITC, complexes formed with 29a
showed low gas-phase stabilities in native MS. Dissociation of
29a fromMabTrmD led to a shift in the charge state distribution
of the protein to lower charge states, which was conﬁrmed for
individual precursor charge states by MS/MS (data not shown).
This could be rationalized by the dissociation of positively
charged 29amolecules fromMab TrmD, leading to a reduction
Figure 4. X-ray crystal structures ofMab TrmD in complex with (a) 26g (PDB code 6QQZ), (b) 27g (PDB code 6QR1), (c) 26j (PDB code 6QR2),
and (d) 26l (PDB code 6QR0), illustrating one of the active sites, andMabTrmD in complex with 26o (PDB code 6QR3), illustrating active sites 1 (e)
and 2 (f).
Table 6. Change in the Melting Temperatures (ΔTm),
Aﬃnities (Kd), and Eﬃciency Metrics of Compounds 28,
29a−e, 30a, and 31a−b
a100 μM ligand and 10 μM Mab TrmD. bkcal mol−1 per heavy atom.
cKd and LE previously reported.
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of the overall positive charge of the protein. In contrast, 24c and
26c, being potentially less cationic than 29a, did not exhibit this
charge reduction behavior. Overall, the native MS data conﬁrm
the direct binding of the ligands toMab TrmD and suggest that
the interaction is speciﬁc, with each Mab TrmD dimer binding
to two molecules of the ligand.
Synthetic Chemistry. Synthesis of compound 2 (Scheme
1) began with addition of a benzyl protecting group to fragment
hit 1 through heating at reﬂux with benzyl bromide in acetone
(93% yield), followed by alkaline hydrolysis of the ester group of
32 to a carboxylic acid (94% yield). Acid 33 was converted by
the action of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
(EDC) to the amide 34 (84% yield) and then debenzylated to 2
Figure 5. X-ray crystal structures ofMab TrmD in complex with 29a (PDB code 6QR6),12 illustrating active sites 1 (a) and 2 (b), andMab TrmD in
complex with (c) 29b (PDB code 6QR7), (d) 29c (PDB code 6QR9), (e) 29d (PDB code 6QR8),12 and (f) 29e (PDB code 6QRD), illustrating one
of the active sites.
Figure 6. Native mass spectrometry of Mab TrmD with compounds 24c, 26c, and 29a. Experiments with ligands contain 5% DMSO.
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through transfer hydrogenation with palladium on carbon,
formic acid, and tert-butanol (64% yield). The production of
esters 3−7 (Scheme 1) started with hydrolysis of 1 to the
corresponding carboxylic acid 35 (96% yield), whose pyrazole
was protected with a tetrahydropyran ring through treatment
with 3,4-dihydro-2H-pyran under acidic conditions to give 36
(43% yield). Carboxylic acid 36 was used to synthesize the ﬁnal
ester compounds 3−7 by two alternative two step protocols,
involving either initial treatment with a benzyl halide and base in
dimethylformamide (DMF) or EDC-mediated ester coupling
with a benzyl alcohol. Both protocols ended with removal of the
tetrahydropyran protecting group by triﬂuoroacetic acid (TFA;
5−57% yield overall).
The routes for synthesis of compounds 8−11 (Scheme 2)
involved protection of phenol 37 with a triisopropylsilyl
protecting group (81% yield), followed by reduction of the
ester group of 38 to the corresponding alcohol 39 using lithium
aluminium hydride (83% yield). Alcohol 39 was put through an
EDC-mediated ester coupling reaction with 36, with the silyl
protecting group removed using tetra-n-butylammonium
ﬂuoride (TBAF; 28% yield overall). Phenol 40 was treated
with an alkyl bromide and base in DMF, and then the
tetrahydropyran-protecting group was removed with TFA to
aﬀord 8 and 9 (50−53% yield overall). In contrast, 10 and 11
were synthesized from 40 through initial coupling with an
alcohol under Mitsunobu conditions with triphenylphosphine
and diisopropyl azodicarboxylate, followed by treatment with
TFA (24−46% yield overall). Compounds 12−15 all utilized
bromoarene 44 in their respective syntheses (Scheme 2), itself
synthesized by a sequence involving methyl iodide alkylation of
41 (97% yield), followed by lithium aluminium hydride
reduction of ester 42 to alcohol 43 (71% yield) that was
coupled with 36 using EDC (63% yield). The Sonogashira cross-
coupling of 44 with alkyne 45, itself produced by treatment of
fragment hit 1 with propargyl bromide in a suspension of
potassium carbonate and DMF (81% yield), aﬀorded 46 (43%
yield). TFA-mediated deprotection of 46 provided 12 (63%
yield). 13 was synthesized by Buchwald−Hartwig amination of
44 with pyrrolidine, followed by TFA deprotection (7% yield
overall). In contrast, 14 was produced through a Suzuki−
Miyaura cross-coupling reaction of 44 with 3-(bromomethyl)-
pyridine, followed by TFA deprotection (44% yield overall). For
15, 44was converted to the corresponding pinacol boronic ester
47 by a Miyaura-borylation with bis(pinacolato)diboron (44%
yield), which was then cross-coupled with 3-(bromomethyl)-
pyridine in a Suzuki−Miyaura reaction and deprotected with
TFA (18% yield overall).
The synthetic route for the 5-aminopyrazole analogue 19
(Scheme 3) began with nucleophilic attack of ester 48 by a
nitrile anion, generated from n-butyllithium and acetonitrile.
This resulted in the corresponding β-ketonitrile 49 (99% yield),
which was heated at reﬂux with hydrazine in ethanol to form 19
(73% yield).25 The synthesis of 23 (Scheme 3) was similar to 19,
using indole 50 as the starting point, which was protected with a
tert-butyldimethylsilyl group to form 51 (59% yield). After
synthesis of the corresponding β-ketonitrile, deprotection was
accomplished by TBAF without prior puriﬁcation aﬀording 52
(99% yield overall), which was heated at reﬂux with hydrazine in
ethanol (59% yield). The deprotected β-ketonitrile 52 was also
utilized in the synthesis of 25 (Scheme 3), with its activated
methylene group treated with trichloroacetonitrile and sodium
acetate.26 The resultant functionalized compound 53 was
puriﬁed (87% yield) before heating at reﬂux with hydrazine in
ethanol to aﬀord 25 (24% yield).
Synthesis of compounds 24a−c and 24f (Scheme 3) utilized
formation of β-ketonitriles 55a−c and 55f from the correspond-
ing methyl esters 54a−c and 54f (84−99% yield) and
subsequent reaction with hydrazine (31−62% yield). Unlike
23, the indole nitrogen was protected by the benzyl or picolyl
groups. In the cases of 54a−d and 54f, these were added to
indole 50 by heating at reﬂux with caesium carbonate and benzyl
or picolyl halides in acetonitrile (80−93% yield). Because of the
production of signiﬁcant amounts of side products in the
synthesis of the corresponding β-ketonitrile from 54d, the
Scheme 1. Synthesis of Compounds 2−7a
aReagents and conditions: (a) BnBr, K2CO3, acetone, reﬂux, 7 h; (b) NaOH, THF, H2O, 70 °C, 150 min; (c) EtNH2·HCl, DIPEA, DMAP, EDC·
HCl, DCM, 15 h; (d) Pd/C (10 wt % loading), formic acid, tBuOH, 50 °C, 2 h; (e) NaOH, H2O, reﬂux, 2 h; (f) 3,4-dihydro-2H-pyran, TsOH·
H2O, EtOAc, DMF, overnight; (g) (i) 4-nitrobenzyl alcohol, DIPEA, DMAP, EDC·HCl, DCM, overnight (ii) TFA, 5 min; (h) (i) RCH2Br,
DIPEA, DMF, 90 min to 2 h (ii) TFA, 10−12 min.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.9b00809
J. Med. Chem. XXXX, XXX, XXX−XXX
I
resultant product was taken forward crude in the synthesis of
24d (18% yield overall) (Scheme 3). The nitrile group of 24d
was also hydrolyzed to an amide, aﬀording 24e (28% yield)
(Scheme 3). Compounds 26c and 26f were synthesized in a
similar manner to 25, using the previously generated β-
ketonitriles 55c and 55f from the production of 24c and 24f
(Scheme 3). However, the intermediates from the reaction with
trichloroacetonitrile were taken forward crude, after aqueous
work up, to the subsequent reaction with hydrazine (45−62%
yield overall).
The production of compounds 26g−m and 27g (Scheme 4)
involved the synthesis of methyl esters 54g−i and 54l−m from
alkylation of indole 50 using a mixture of the corresponding
electrophile with sodium hydride in DMF. Following the
consumption of starting material, the reaction was diluted with
methanol and sulfuric acid and heated at reﬂux to recover the
carboxylic acid side-product. While the electrophiles for the
synthesis of methyl esters 54g and 54l were commercially
available, 54h−i and 54m required the synthesis of precursors.
Alkyl halide 58 for 54i was generated from alcohol 57 by
treatment with tosyl chloride and DMAP (17% yield), itself
produced by the reduction of ester 56 using lithium aluminium
hydride (91% yield). Alcohol 60, itself a product of the
reduction of ester 59 using sodium borohydride (67% yield),
Scheme 2. Synthesis of Compounds 8−15a
aReagents and conditions: (a) TIPSCl, imidazole, DMF, 2 h; (b) LiAlH4 (2.4 M in THF), Et2O, 0 °C to rt, 3 h; (c) (i) 36, DIPEA, DMAP, EDC·
HCl, DCM, overnight (ii) TBAF (1 M in THF), 10 min; (d) (i) Cs2CO3, RCH2Br (·HBr), DMF, 2 h (ii) TFA, 15 min; (e) (i) PPh3, RCH2OH,
DIAD, THF, 1 h to overnight (ii) TFA, 15 min; (f) MeI, K2CO3, DMF, 3 d; (g) LiAlH4 (2.4 M in THF), Et2O, 0 °C to rt, overnight; (h) 36,
DIPEA, DMAP, EDC·HCl, DCM, overnight; (i) propargyl bromide (80 wt % solution in toluene), K2CO3, DMF, 3 d; (j) 44, Pd(dppf)Cl2, CuI,
NEt3, DMF, 100 °C, 4 h; (k) TFA, 15 min; (l) (i) pyrrolidine, Cs2CO3, RuPhos, RuPhos Pd G1 methyl tert-butyl ether adduct,
tBuOH, 85 °C, 15 h
(ii) TFA, 30 min; (m) (i) 3-pyridinylboronic acid, Pd(dppf)Cl2, K2CO3, dioxane, H2O, 100 °C μW, 30 min (ii) TFA, 15 min; (n) B2pin2,
Pd(dppf)Cl2, KOAc, dioxane, 80 °C, 3 h; (o) (i) 3-(bromomethyl)pyridine HBr, Pd(PPh3)4, K2CO3, DME, H2O, 95 °C, 10 h (ii) TFA, 30 min.
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was treated with tosyl chloride in a similar manner to 57;
however, the product was taken forward crude for reaction with
indole 50 to aﬀord 54h (31% yield overall). With 54m, aldehyde
61 was reduced to the corresponding alcohol 62 by sodium
borohydride (79% yield),27 which was heated at reﬂux in
aqueous HBr to aﬀord a crude material that was taken forward
for reaction with 50 (65% yield overall). Themethyl esters 54g−
i and 54l−m were converted to the corresponding β-ketonitriles
55g−i and 55l−m (26−82% yield), which were used to produce
the 4-cyanopyrazole compounds in the same manner as 26c and
26f (41−61% yield overall). 2-Hydroxypyridyl/pyridone
compounds 26j and 26k were synthesized from methoxypyridyl
precursors 26h and 26i, respectively, using nucleophilic
demethylation with lithium chloride and p-toluenesulfonic
acid in DMF (47−51% yield).28 Meanwhile, 3-chloroindole
derivative 27g was synthesized directly from 26g through
treatment with N-chlorosuccinimide in DMF (63% yield).
Synthesis of compounds 26n and 26o (Scheme 4) began with
conversion of racemic alcohols 63 and 65, respectively, to
electrophilic alkylating agents. Alkyl chloride 64 was produced
from 63 using thionyl chloride (58% yield), while treatment of
65 with tosyl chloride, triethylamine, and DMAP generated the
alkyl tosylate 66 (36% yield). Synthesis of the methyl esters
54n−o from indole 50 and the agents 64 and 66 with sodium
hydride in DMF involved heating at 60 °C (27−45% yield), with
NaI also added as a catalyst for 54o. These esters were converted
to the corresponding β-ketonitriles 55n−o (32−67% yield),
which were used to produce the 4-cyanopyrazole compounds in
the same manner as 26c and 26f (38−57% yield overall).
Synthesis of 28 (Scheme 5) began with regioselective
reduction of diester 67 using a combination of sodium
borohydride and CaCl2 (84% yield),
29 with protection of the
resultant alcohol 68 as a tetrahydropyranyl ether in 69 (77%
yield). The ester of 69 was reduced with lithium aluminium
hydride to the corresponding alcohol 70 (64% yield), which was
converted to a mesylate then reacted with pyrrolidine and
Cs2CO3 in DMF to aﬀord 71 (66% yield overall). The
tetrahydropyranyl ether 71 was deprotected with p-toluene-
sulfonic acid in ethanol (86% yield), and the resultant alcohol 72
converted to a mesylate that was reacted with indole 50 using
Scheme 3. Synthesis of Compounds 19, 23, 24a−f, 25, 26c, and 26fa
aReagents and conditions: (a) n-butyllithium (1.6 M in hexanes), acetonitrile, THF, −78 °C, 30 min; (b) N2H4·H2O, EtOH, reﬂux, 6 h; (c) NaH,
TBDMSCl, THF, 0 °C to rt, 10 h; (d) (i) n-butyllithium (1.6 M in hexanes), acetonitrile, toluene, −78 °C, 1 h (ii) TBAF (1 M in THF), THF, 20
min; (e) N2H4·H2O, EtOH, reﬂux, 12 h; (f) CCl3CN, NaOAc, EtOH, 90 min; (g) N2H4·H2O, EtOH, reﬂux, 22 h; (h) RCH2X (·HX), Cs2CO3,
acetonitrile, reﬂux, 1−15 h; (i) n-butyllithium (1.6 M in hexanes), acetonitrile, toluene/THF, −78 °C, 15 min to 1 h; (j) N2H4·H2O, EtOH, reﬂux,
5−13 h; (k) (i) n-butyllithium (1.6 M in hexanes), acetonitrile, toluene, −78 °C, 1 h (ii) N2H4·H2O, EtOH, reﬂux, 5 h; (l) NaOH, H2O, 100 °C, 7
h; (m) (i) CCl3CN, NaOAc, EtOH, 90 min to 9 h (ii) N2H4·H2O, EtOH, reﬂux, 5−15 h.
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sodium hydride and NaI in DMF at elevated temperatures (7%
yield overall). The methyl ester 73 was converted to the
corresponding β-ketonitrile 74 (71% yield), which was used to
produce 28 in the same manner as 26c and 26f (6% yield
overall). Compounds 29a−e (Scheme 5) were all produced
from methyl esters 79a−e. Esters 79a−d were synthesized by
the microwave-assisted condensation of aldehydes 78a−d and
indoline 75 (53−67% yield),30 itself produced by the reduction
of indole 50 using sodium cyanoborohydride in acetic acid (66%
yield).31 Aldehydes 78a−d were generated in two steps by
reductive amination of 4-cyanobenzaldehyde 76 with various
secondary amines to form 77a−d (70−85% yield), followed by
reduction using diisobutylaluminium hydride (46−75% yield).
In comparison, ester 79e required the protection of one of the
alcohols of 80 with a tert-butyldiphenylsilyl group (38% yield),
followed by conversion of the remaining alcohol of 81 to a crude
mixture of the mesylate and chloride that was used to alkylate 50
with sodium hydride andDMF, with subsequent deprotection of
Scheme 4. Synthesis of Compounds 26g−o and 27ga
aReagents and conditions: (a) LiAlH4, THF, 0 °C, 1 h; (b) TsCl, DMAP, NEt3, DCM, 18 h; (c) (i) RCH2X·HX (58 for 54i), NaH, DMF, 0 °C to
rt, 45 min to 1 h (ii) MeOH, H2SO4, reﬂux, 1−16 h; (d) NaBH4, EtOH, 0 °C to rt, 1 d; (e) (i) TsCl, DMAP, NEt3, DCM, 2 h (ii) 50, NaH, DMF,
0 °C to rt, 30 min (iii) MeOH, H2SO4, reﬂux, 90 min; (f) NaBH4, MeOH, 0 °C, 90 min; (g) (i) aqueous HBr (48%), reﬂux, 90 min (ii) 50, NaH,
DMF, 0 °C to rt, 15 min (iii) MeOH, H2SO4, reﬂux, 2 h; (h) n-butyllithium (1.6 M in hexanes), acetonitrile, toluene/THF, −78 °C, 30 min to 1 h;
(i) (i) CCl3CN, NaOAc, EtOH, 13−36 h (ii) N2H4·H2O, EtOH, reﬂux, 6−21 h; (j) NCS, DMF, 7 h 30 min; (k) LiCl, TsOH·H2O, DMF, 120 °C,
25 min; (l) SOCl2, DCM, reﬂux, 7 h; (m) 50, NaH, DMF, 0−60 °C, 1 h (ii) MeOH, H2SO4, reﬂux, 1 h; (n) TsCl, DMAP, NEt3, DCM, 4 h; (o)
(i) 50, NaH, NaI, DMF, 0−60 °C, 1 h; (p) n-butyllithium (1.6 M in hexanes), acetonitrile, THF, −78 °C, 30 min to 1 h; (q) (i) CCl3CN, NaOAc,
EtOH, 3 h 30 min to 18 h (ii) N2H4·H2O, EtOH, reﬂux, 15 h to 1 d.
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the silyl protecting group with TBAF (72% yield overall). The
benzyl alcohol of 82 was treated with mesyl chloride and
triethylamine, then functionalized with 1-isopropylpiperazine to
aﬀord 79e (43% yield overall). The methyl esters 79a−e were
converted to the corresponding β-ketonitriles 83a−e (77−87%
yield), which were used to produce 29a−e in the same manner
as 26c and 26f (32−75% yield overall) or 31a−b by heating at
reﬂux with hydrazine in ethanol (22−52% yield). Methyl ester
79a was also used to produce 30a (Scheme 5) through initial
treatment with n-butyllithium and propionitrile to aﬀord β-
ketonitrile 84a (35% yield), which was then heated at reﬂux with
hydrazine in ethanol (21% yield).
Scheme 5. Synthesis of Compounds 28, 29a−e, 30a, and 31a−ba
aReagents and conditions: (a) NaBH4, CaCl2, MeOH, THF, 0 °C, 90 min; (b) MsOH, 3,4-dihydro-2H-pyran, DCM, 150 min; (c) LiAlH4, THF, 0
°C, 45 min; (d) (i) MsCl, NEt3, DCM, 0 °C to rt, 1 h (ii) pyrrolidine, Cs2CO3, DMF, 14 h; (e) TsOH·H2O, ethanol, 50 °C, 30 min; (f) (i) MsCl,
NEt3, DCM, 0 °C to rt, 150 min; (ii) 50, NaH, NaI, DMF, 0 to 60 °C, 75 min (iii) MeOH, H2SO4, reﬂux, 14 h; (g) n-butyllithium (1.6 M in
hexanes), acetonitrile, THF, −78 °C, 1 h; (h) (i) CCl3CN, NaOAc, EtOH, 36 h (ii) N2H4·H2O, EtOH, reﬂux, 1 d; (i) NaCNBH3, AcOH, 0 °C to
rt, 7 h; (j) Na(OAc)3BH, RH, AcOH, DCM, 80 min to 15 h; (k) DIBAL-H, THF, 0 °C to rt, 90 min to 1 h; (l) PhCO2H, toluene, 200 °C μW,
20−30 min; (m) TBDPSCl, imidazole, DMF, 21 h; (n) (i) MsCl, NEt3, DCM, 0 °C to rt, 1 h (ii) 50, NaH, DMF, 0 °C to rt, 45 min (iii) TBAF (1
M in THF), 30 min; (o) (i) MsCl, NEt3, DCM, 0 °C to rt, 90 min (ii) RH, Cs2CO3, DMF, 12 h; (p) n-butyllithium (1.6 M in hexanes),
acetonitrile, THF, −78 °C, 20 min to 1 h; (q) (i) CCl3CN, NaOAc, EtOH, 4 h to 2 d (ii) N2H4·H2O, EtOH, reﬂux, 7 h to 1 d; (r) N2H4·H2O,
EtOH, reﬂux, 12−21 h; (s) n-butyllithium (1.6 M in hexanes), propionitrile, toluene, −78 to 0 °C, 2 h; (t) N2H4·H2O, EtOH, reﬂux, 1 d.
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Screening of Compounds against Mycobacteria. The
eﬀect of compounds on Mab and Mtb growth in liquid culture
was determined and revealed promising minimal inhibitory
concentrations (MIC) for many compounds (Table 7). A lack of
correlation between target binding aﬃnity and activity against
bacteria was observed, indicating likely eﬀects of diﬀerential
permeability, retention, and metabolism of compounds on their
in vitro activity. While compounds performed similarly against
Mab, 29e aﬀorded the best results against Mtb across diﬀerent
media types and carbon sources, with MIC values of 1.6 and 2.3
μM achieved with 7H9 supplemented by dipalmitoyl
phosphatidylcholine (DPPC) and glucose respectively. Both
glucose and DPPC are carbon sources predicted to be relevant
during the in vivo pathogenesis ofMtb,32 and the activity of the
compounds during catabolism of both of these supports the
notion that TrmD inhibition will inhibit bacterial growth under
any metabolic condition. The poor activity in 7H9/ADC was
likely due to high protein binding because this medium contains
0.4% bovine serum albumin. Hence, overcoming protein
binding will be an important component of future drug design
strategies.
In addition to the results against Mab and Mtb in liquid
culture, activity was observed by compounds from the lead series
in macrophage infection models against Mab and M. leprae,
demonstrating the utility of the series against mycobacteria in
vivo.12
■ CONCLUSIONS
With the application of a fragment-growing approach to a highly
ligand-eﬃcient fragment hit of Mab TrmD failing to aﬀord a
signiﬁcant improvement in binding aﬃnity, a fragment-merging
approach was explored. The combination of structural features
of two fragments, 16 (Kd 170 μM, LE 0.37) and 20 (Kd 0.26mM,
LE 0.41), proved promising with the resultant aminopyrazole-
indole compound 23 (Kd 110 μM, LE 0.36) possessing
improved aﬃnity. Controlled elaboration with 23, guided by
extensive structural information and biophysical data, resulted in
the development of a ligand-eﬃcient low-nanomolar aﬃnity
compound 29a (Kd 27 nM, LE 0.34) against Mab TrmD.
Compounds from this fragment-merging series were sub-
sequently screened against both Mab and Mtb growth in liquid
culture, with many aﬀording promising MIC values. These
results are encouraging and support the use of TrmD as a target
for the development of compounds with antimycobacterial
activity. As a result, the work described in this study is currently
being developed in the pursuit of further compounds with
potent activity against Mab.
■ EXPERIMENTAL SECTION
General Chemistry. All reactions were carried out in oven-dried
glassware under a positive pressure of dry nitrogen atmosphere.
Temperatures of 0 and −78 °C were obtained by submerging the
reaction vessel in a bath containing either ice or a mixture of solid CO2
pellets and acetone respectively. The solvents dichloromethane
(DCM), ethyl acetate, acetonitrile, methanol, petroleum ether, and
toluene were distilled over calcium hydride under a dry nitrogen
atmosphere prior to use, with tetrahydrofuran (THF) distilled over a
mixture of lithium aluminium hydride, calcium hydride, and
triphenylphosphine. DMF was purchased as anhydrous from
commercial suppliers, with ethanol and acetic acid obtained in the
absolute and glacial forms, respectively. All purchased chemicals were
used as received. Solutions of Na2CO3, NaHCO3, NaCl (brine), and
NH4Cl were aqueous and saturated. Solutions of LiCl were aqueous
and 5% w/v.
Flash column chromatography was performed using automated
Biotage Isolera Spektra puriﬁcation systems with appropriately sized
Biotage SNAP cartridges, containing either KP 50 μm silica in “normal
phase” puriﬁcation or HP-sphere 25 μm C18 silica in “reverse phase”
puriﬁcation.Microwave heating was performed using a Biotage Initiator
+ system with sealed Biotage microwave reaction vials. Analytical thin
layer chromatography (TLC) was performed using Merck glass-backed
silica plates, with visualization by 254 or 365 nm ultraviolet light.
Liquid chromatography mass spectrometry (LCMS) was carried out
using a Waters Acquity UPLC H-Class system, with samples run on a
solvent gradient from 0 to 95% acetonitrile in water (+0.1% formic
acid) over 4 min. Peaks corresponding to the desired product are
described, including the retention time (rt) and % purity by integration.
High resolution mass spectrometry (HRMS) was mainly performed
using ThermoFinnigan Orbitrap Classic, Waters LCT Premier or
Waters Vion IMS QTof systems. A PerkinElmer Spectrum One FT-IR
spectrometer ﬁtted with a universal attenuated total reﬂectance
accessory was used to record infrared spectra, with wavelengths of
maximum absorbance (νmax) quoted in wavenumbers (cm
−1) for signals
outside of the ﬁngerprint region (br = broad). Only peaks
corresponding to key functional groups were characterized. Nuclear
magnetic resonance (NMR) spectra were recorded in the indicated
deuterated solvents with Avance III HD (400 MHz), QNP Cryoprobe
(400MHz), or DCHCryoprobe (500MHz) Bruker spectrometers. 1H
NMR data are presented in the following order: chemical shift (in ppm
on a δ scale relative to the residual solvent resonance peak), integration,
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, quin =
quintet, sep = septet, m = multiplet), and coupling constant (J, in Hz).
13C NMR spectra were proton-decoupled, with chemical shifts
recorded, and further description are provided for certain peaks (br =
broad).
A combination of TLC and LCMS analysis was used to monitor
reactions. All tested compounds possessed a purity of at least 95% as
determined by LCMS analysis (except for compound 2, for which
LCMS analysis was not possible).
Table 7. Minimum Inhibitory Concentrations (MIC) against Mab and Mtb of Compounds 26l, 28, 29a−e, and 31a−b
H37Rv Mtb MIC (μM)
compound Mab TrmD Kd (μM) Mab MIC (μM) GAST-Fe 7H9/ADC 7H9/glucose 7H9/DPPC
26l 0.12 ± 0.02 50 50 >100 ND ND
28 0.092 ± 0.018 50 ND ND ND ND
29aa 0.027 ± 0.004 50 50 >100 25 12.5
29b 0.070 ± 0.029 50 50 100 25 12.5
29c 0.19 ± 0.02 50 50 >100 100 50
29da 0.073 ± 0.030 50 25 50 12.5 6.3
29e 0.10 ± 0.02 50 6.3 12.5 2.3 1.6
31aa 0.49 ± 0.21 50 25 100 12.5 6.3
31b 0.71 ± 0.09 50 50 >100 25 12.5
aMab MIC and H37Rv Mtb MIC (7H9/DPPC) previously reported.12
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The synthesis of 23, 24f, 26f, 28, 29a, 29d, and 31a, and associated
intermediates including 51, 52, 54f, 55f, 68−75, 77a, 77d, 78a, 78d,
79a, 79d, 83a, and 83d, have previously been reported.12
N-Ethyl-1H-pyrazole-4-carboxamide (2). Palladium on carbon
(10 wt % loading, 0.150 g) was added to a suspension of 1-benzyl-N-
ethyl-1H-pyrazole-4-carboxamide 34 (75 mg, 0.33 mmol) in tert-
butanol (15 mL) and formic acid (1.5 mL). The reaction mixture was
heated to 50 °C over 2 h, then ﬁltered, and concentrated in vacuo.
Puriﬁcation by ﬂash column chromatography (0−15% methanol in
DCM) aﬀorded 2 (29 mg, 64% yield). 1H NMR: (400 MHz, CD3OD)
8.03 (2H, s), 3.36 (2H, q, J = 7.3 Hz), 1.20 (3H, t, J = 7.3 Hz); 13C
NMR: (100 MHz, CD3OD) 165.3, 119.1, 35.2, 15.0 (1 peak missing);
νmax/cm
−1: 3302 (N−H), 3110, 2974, 2876, 1632 (CO), 1584, 1541,
1515; HRMS (ESI)+: m/z calcd for [C6H9N3O + H]
+, 140.0818;
observed, 140.0818.
Benzyl 1H-Pyrazole-4-carboxylate (3). Benzyl bromide (0.11
mL, 0.92 mmol) and N,N-diisopropylethylamine (0.20 mL, 1.1 mmol)
were added to a solution of 1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-
4-carboxylic acid 36 (0.150 g, 0.765 mmol) in DMF (2.5 mL). The
reaction mixture was stirred over 2 h, then diluted with ethyl acetate
(200 mL), washed with LiCl solution (2× 100 mL) and brine (2× 200
mL), dried (MgSO4), and concentrated in vacuo to aﬀord the crude
reaction intermediate. TFA (1mL)was added, and the reactionmixture
was stirred over 12min, then diluted withNaHCO3 solution (20mL) at
0 °C, and extracted into DCM (3 × 50 mL). The combined organic
extracts were washed with NaHCO3 solution (50 mL) and brine (50
mL), dried (MgSO4), and concentrated in vacuo. Puriﬁcation by ﬂash
column chromatography (0−85% ethyl acetate in petroleum ether)
aﬀorded 3 (76 mg, 50% yield). LCMS (ESI+): m/z 203.2 [M + H]+,
(ESI−):m/z 201.1 [M−H]−, rt 1.61 min, >99%; 1HNMR: (500MHz,
CDCl3) 10.83 (1H, br s), 8.09 (2H, s), 7.45−7.32 (5H, m), 5.31 (2H,
s); 13C NMR: (125 MHz, CDCl3) 163.0, 136.8 (br), 136.2, 128.7,
128.41, 128.36, 115.1, 66.2; νmax/cm
−1: 3168, 3124, 3043, 2947, 2835,
1714, 1702 (CO), 1578, 1521; HRMS (ESI)+: m/z calcd for
[C11H10N2O2 + H]
+, 203.0815; observed, 203.0823.
4-Nitrobenzyl 1H-Pyrazole-4-carboxylate (4). EDC·HCl
(0.293 g, 1.53 mmol) was added to a solution of 1-(tetrahydro-2H-
pyran-2-yl)-1H-pyrazole-4-carboxylic acid 36 (0.200 g, 1.02 mmol), 4-
nitrobenzyl alcohol (0.188 g, 1.22 mmol), N,N-diisopropylethylamine
(0.267 mL, 1.53 mmol), and DMAP (19 mg, 0.15 mmol) in DCM (5
mL). The reaction mixture was stirred overnight, then diluted with
water (30 mL), and extracted into DCM (3 × 20 mL). The combined
organic extracts were washed (brine), dried (MgSO4), and concen-
trated in vacuo. Puriﬁcation by ﬂash column chromatography (30−80%
ethyl acetate in petroleum ether) aﬀorded the reaction intermediate.
TFA (2 mL) was added to a solution of the reaction intermediate in
DCM (4mL). The reactionmixture was stirred over 5min, then diluted
with NaHCO3 solution (50 mL) at 0 °C, and extracted into DCM (3 ×
50 mL). The combined organic extracts were washed (brine), dried
(MgSO4), and concentrated in vacuo. Puriﬁcation by ﬂash column
chromatography (0−7% methanol in DCM) aﬀorded 4 (98 mg, 40%
yield). LCMS (ESI−): m/z 246.1 [M − H]−, rt 1.62 min, >99%; 1H
NMR: (400MHz, CDCl3) 8.27−8.22 (2H, m), 8.11 (2H, s), 7.58 (2H,
d, J = 8.9 Hz), 5.40 (2H, s); 13C NMR: (100 MHz, CDCl3) 162.6,
147.9, 143.5, 136.9, 128.5, 124.0, 114.4, 64.7; νmax/cm
−1: 3120, 2930,
2855, 1715 (CO), 1606, 1518 (N−O), 1342 (N−O); HRMS
(ESI)−: m/z calcd for [C11H9N3O4 − H]−, 246.0520; observed,
246.0512.
4-(Methoxycarbonyl)benzyl 1H-Pyrazole-4-carboxylate (5).
Methyl-4-(bromomethyl) benzoate (0.248 g, 1.08 mmol) and N,N-
diisopropylethylamine (0.24mL, 1.5 mmol) were added to a solution of
1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-4-carboxylic acid 36 (0.177
g, 0.903 mmol) in DMF (3 mL). The reaction mixture was stirred over
2 h, then diluted with ethyl acetate (200 mL), washed with LiCl
solution (2 × 100 mL) and brine (2 × 200 mL), dried (MgSO4), and
concentrated in vacuo to aﬀord the crude reaction intermediate. TFA
(2 mL) was added, and the reaction mixture was stirred over 10 min,
then diluted withNaHCO3 solution (50mL) at 0 °C, and extracted into
DCM (3 × 50 mL). The combined organic extracts were washed with
NaHCO3 solution (50 mL) and brine (50 mL), dried (MgSO4), and
concentrated in vacuo. Puriﬁcation by ﬂash column chromatography
(0−70% ethyl acetate in petroleum ether) aﬀorded 5 (0.115 g, 49%
yield). LCMS (ESI−): m/z 259.1 [M − H]−, rt 1.62 min, >99%; 1H
NMR: (400MHz, CDCl3) 8.10 (2H, s), 8.08−8.02 (2H, m), 7.48 (2H,
d, J = 8.2 Hz), 5.36 (2H, s), 3.92 (3H, s); 13C NMR: (100 MHz,
CDCl3) 166.9, 162.8, 141.2, 136.9, 130.1, 130.0, 127.8, 114.7, 65.4,
52.4; νmax/cm
−1: 3114, 2950, 1712 (CO), 1617, 1578, 1523; HRMS
(ESI)+: m/z calcd for [C13H12N2O4 + H]
+, 261.0870; observed,
261.0860.
3-Cyanobenzyl 1H-Pyrazole-4-carboxylate (6). 3-
(Bromomethyl)benzonitrile (0.360 g, 1.84 mmol) and N,N-diisopro-
pylethylamine (0.53 mL, 3.1 mmol) were added to a solution of 1-
(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-4-carboxylic acid 36 (0.300 g,
1.53mmol) in DMF (3.5mL). The reactionmixture was stirred over 90
min, then diluted with ethyl acetate (200 mL), washed with LiCl
solution (2 × 100 mL) and brine (2 × 200 mL), dried (MgSO4), and
concentrated in vacuo to aﬀord the crude reaction intermediate. TFA
(2 mL) was added, and the reaction mixture was stirred over 10 min,
then diluted withNaHCO3 solution (50mL) at 0 °C, and extracted into
DCM (3 × 50 mL). The combined organic extracts were washed with
NaHCO3 solution (50 mL) and brine (50 mL), dried (MgSO4), and
concentrated in vacuo. Puriﬁcation by ﬂash column chromatography
(0−10% methanol in DCM) aﬀorded 6 (0.197 g, 57% yield). LCMS
(ESI−): m/z 226.1 [M −H]−, rt 1.54 min, 96%; 1H NMR: (500 MHz,
CDCl3) 8.10 (2H, s), 7.74−7.70 (1H, m), 7.67−7.61 (2H, m), 7.50
(1H, t, J = 7.8 Hz), 5.32 (2H, s); 13C NMR: (125 MHz, CDCl3) 162.6,
137.8, 136.9, 132.5, 132.0, 131.6, 129.6, 118.6, 114.4, 113.0, 64.8; νmax/
cm−1: 3179, 3125, 2951, 2227 (CN), 1721 (CO), 1576, 1522;
HRMS (ESI)+: m/z calcd for [C12H9N3O2 + H]
+, 228.0768; observed,
228.0782.
3-Methoxybenzyl 1H-Pyrazole-4-carboxylate (7). 3-Methox-
ybenzyl bromide (0.13 mL, 0.92 mmol) and N,N-diisopropylethyl-
amine (0.20 mL, 1.1 mmol) were added to a solution of 1-(tetrahydro-
2H-pyran-2-yl)-1H-pyrazole-4-carboxylic acid 36 (0.150 g, 0.765
mmol) in DMF (2.5 mL). The reaction mixture was stirred over 2 h,
then diluted with ethyl acetate (200 mL), washed with LiCl solution (2
× 100 mL) and brine (2 × 200 mL), dried (MgSO4), and concentrated
in vacuo. Puriﬁcation by ﬂash column chromatography (0−85% ethyl
acetate in petroleum ether) aﬀorded the reaction intermediate. TFA (1
mL) was added, and the reaction mixture was stirred over 10 min, then
diluted with NaHCO3 solution (20 mL) at 0 °C, and extracted into
DCM (3 × 15 mL). The combined organic extracts were washed with
NaHCO3 solution (50 mL) and brine (50 mL), dried (MgSO4), and
concentrated in vacuo. Puriﬁcation by ﬂash column chromatography
(30−60% ethyl acetate in petroleum ether) aﬀorded 7 (8.2 mg, 5%
yield). LCMS (ESI−): m/z 231.2 [M − H]−, rt 1.64 min, 98%; 1H
NMR: (400 MHz, CDCl3) 8.09 (2H, s), 7.30 (1H, t, J = 7.9 Hz), 7.00
(1H, d, J = 7.7 Hz), 6.97−6.93 (1H, m), 6.88 (1H, dd, J = 8.1, 2.5 Hz),
5.28 (2H, s), 3.82 (3H, s); 13C NMR: (100MHz, CDCl3) 162.9, 159.9,
137.7, 136.9, 129.8, 120.5, 115.0, 113.9, 113.8, 66.1, 55.4; νmax/cm
−1:
3276, 3113, 2942, 1718, 1678 (CO), 1598, 1558; HRMS (ESI)+:m/
z calcd for [C12H12N2O3 + H]
+, 233.0921; observed, 233.0927.
3-(2-Methoxy-2-oxoethoxy)benzyl 1H-Pyrazole-4-carboxy-
late (8). Caesium carbonate (0.336 g, 1.03 mmol) and methyl
bromoacetate (54 μL, 0.57 mmol) were added to a solution of 3-
hydroxybenzyl 1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-4-carboxy-
late 40 (0.156 mg, 0.516 mmol) in DMF (3 mL). The reaction mixture
was stirred over 2 h, then diluted with ethyl acetate (200 mL), washed
with LiCl solution (2 × 100 mL) and brine (2 × 200 mL), dried
(MgSO4), and concentrated in vacuo to aﬀord the crude reaction
intermediate. TFA (2 mL) was added, and the reaction mixture was
stirred over 15 min, then diluted with NaHCO3 solution (50 mL) at 0
°C, and extracted into DCM (3 × 50 mL). The combined organic
extracts were washed with NaHCO3 solution (50 mL) and brine (50
mL), dried (MgSO4), and concentrated in vacuo. Puriﬁcation by ﬂash
column chromatography (0−100% ethyl acetate in petroleum ether)
aﬀorded 8 (75 mg, 50% yield). LCMS (ESI+): m/z 291.2 [M + H]+,
(ESI−):m/z 289.1 [M−H]−, rt 1.61 min, >99%; 1HNMR: (400MHz,
CDCl3) 10.75 (1H, br s), 8.08 (2H, s), 7.30 (1H, t, J = 7.9 Hz), 7.05
(1H, d, J = 7.5 Hz), 6.98 (1H, s), 6.86 (1H, dd, J = 8.2, 2.2 Hz), 5.27
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(2H, s), 4.65 (2H, s) 3.80 (3H, s); 13C NMR: (100 MHz, CDCl3)
169.5, 162.9, 158.1, 138.0, 137.0 (br), 130.0, 121.6, 114.9, 114.6, 114.3,
65.8, 65.5, 52.5; νmax/cm
−1: 3303, 1745 (CO), 1714 (CO), 1587,
1561; HRMS (ESI)+: m/z calcd for [C14H14N2O5 + Na]
+, 313.0795;
observed, 313.0792.
3-(Pyridin-2-ylmethoxy)benzyl 1H-Pyrazole-4-carboxylate
(9). Caesium carbonate (0.970 g, 2.98 mmol) and 2-bromomethylpyr-
idine hydrobromide (0.282 g, 1.09mmol) were added to a solution of 3-
hydroxybenzyl 1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-4-carboxy-
late 40 (0.300 g, 0.992 mmol) in DMF (3.5 mL). The reaction mixture
was stirred over 2 h, then diluted with ethyl acetate (80 mL), washed
with LiCl solution (2 × 100 mL) and brine (2 × 150 mL), dried
(MgSO4), and concentrated in vacuo to aﬀord the crude reaction
intermediate. TFA (2 mL) was added, and the reaction mixture was
stirred over 15 min, then diluted with NaHCO3 solution (50 mL) at 0
°C, and extracted into DCM (3 × 50 mL). The combined organic
extracts were washed with NaHCO3 solution (50 mL) and brine (50
mL), dried (MgSO4), and concentrated in vacuo. Puriﬁcation by ﬂash
column chromatography (20−100% ethyl acetate in petroleum ether)
aﬀorded 9 (0.163 g, 53% yield). LCMS (ESI+): m/z 310.2 [M + H]+,
(ESI−): m/z 308.1 [M − H]−, rt 1.55 min, 97%; 1H NMR: (400 MHz,
CDCl3) 11.01 (1H, br s), 8.59 (1H, d, J = 4.8 Hz), 8.08 (2H, s), 7.72
(1H, td, J = 7.7, 1.7 Hz), 7.52 (1H, d, J = 7.8 Hz), 7.29 (1H, t, J = 7.9
Hz), 7.23 (1H, dd, J = 7.1, 5.1 Hz), 7.08−7.04 (1H, m), 7.01 (1H, d, J =
7.7 Hz), 6.95 (1H, dd, J = 8.2, 2.2 Hz), 5.27 (2H, s), 5.22 (2H, s); 13C
NMR: (100 MHz, CDCl3) 162.9, 158.7, 157.2, 149.3, 137.9, 137.1,
129.9, 122.9, 121.5, 120.9, 114.9, 114.7, 114.6, 70.7, 65.9 (1 peak
missing); νmax/cm
−1: 3118, 2947, 1707 (CO), 1598, 1570, 1516;
HRMS (ESI)−: m/z calcd for [C17H15N3O3 − H]−, 308.1041;
observed, 308.1030.
3-Ethoxybenzyl 1H-Pyrazole-4-carboxylate (10). Triphenyl-
phosphine (0.217 g, 0.831 mmol), ethanol (49 μL, 0.83 mmol), and
diisopropyl azodicarboxylate (0.16 mL, 0.83 mmol) were added to a
solution of 3-hydroxybenzyl 1-(tetrahydro-2H-pyran-2-yl)-1H-pyra-
zole-4-carboxylate 40 (0.250 g, 0.831 mmol) in THF (5 mL). The
reaction mixture was stirred over 1 h, then diluted with NaHCO3
solution (35 mL), and extracted into diethyl ether (3 × 30 mL). The
combined organic extracts were washed with NaHCO3 solution (40
mL) and brine (40 mL), dried (Na2SO4), and concentrated in vacuo.
Puriﬁcation by ﬂash column chromatography (20−100% ethyl acetate
in petroleum ether) aﬀorded the reaction intermediate. TFA (2 mL)
was added, and the reaction mixture was stirred over 15 min, then
diluted with NaHCO3 solution (50 mL) at 0 °C, and extracted into
DCM (3 × 50 mL). The combined organic extracts were washed
(brine), dried (MgSO4), and concentrated in vacuo. Puriﬁcation by
ﬂash column chromatography (0−90% ethyl acetate in petroleum
ether) aﬀorded 10 (94 mg, 46% yield). LCMS (ESI+):m/z 247.2 [M +
H]+, (ESI−): m/z 245.1 [M −H]−, rt 1.79 min, >99%; 1H NMR: (500
MHz, CDCl3) 8.09 (2H, s), 7.28 (1H, t, J = 7.9 Hz), 6.98 (1H, d, J = 7.5
Hz), 6.96−6.94 (1H, m), 6.86 (1H, dd, J = 8.2, 2.4 Hz), 5.27 (2H, s),
4.04 (2H, q, J = 7.0 Hz), 1.41 (3H, t, J = 7.0 Hz); 13CNMR: (125MHz,
CDCl3) 163.0, 159.3, 137.6, 136.9, 129.8, 120.4, 115.0, 114.4, 114.3,
66.1, 63.6, 15.0; νmax/cm
−1: 3256, 3118, 2979, 2942, 2888, 1686 (C
O), 1601, 1559; HRMS (ESI)+: m/z calcd for [C13H14N2O3 + H]
+,
247.1077; observed, 247.1084.
3-Phenethoxybenzyl 1H-Pyrazole-4-carboxylate (11). Tri-
phenylphosphine (0.261 g, 0.997 mmol), phenethyl alcohol (0.12
mL, 1.0 mmol), and diisopropyl azodicarboxylate (0.20 mL, 1.0 mmol)
were added to a solution of 3-hydroxybenzyl 1-(tetrahydro-2H-pyran-
2-yl)-1H-pyrazole-4-carboxylate 40 (0.300 g, 0.997 mmol) in THF (5
mL). The reaction mixture was stirred overnight, then diluted with
NaHCO3 solution (30 mL), and extracted into diethyl ether (3 × 30
mL). The combined organic extracts were washed with NaHCO3
solution (40 mL) and brine (40 mL), dried (Na2SO4), and
concentrated in vacuo. Puriﬁcation by ﬂash column chromatography
(0−100% ethyl acetate in petroleum ether) aﬀorded the reaction
intermediate. TFA (2 mL) was added, and the reaction mixture was
stirred over 15 min, then diluted with NaHCO3 solution (50 mL) at 0
°C, and extracted into DCM (3 × 50 mL). The combined organic
extracts were washed with NaHCO3 solution (50 mL) and brine (50
mL), dried (MgSO4), and concentrated in vacuo. Puriﬁcation by ﬂash
column chromatography (0−100% ethyl acetate in petroleum ether)
aﬀorded 11 (77 mg, 24% yield). LCMS (ESI+): m/z 323.2 [M + H]+,
(ESI−):m/z 321.1 [M−H]−, rt 2.08 min, >99%; 1HNMR: (500MHz,
CDCl3) 10.69 (1H, br s), 8.08 (2H, s), 7.35−7.21 (6H, m), 7.01−6.97
(1H, m), 6.95 (1H, t, J = 1.9 Hz), 6.87 (1H, ddd, J = 8.3, 2.5, 0.7 Hz),
5.26 (2H, s), 4.19 (2H, t, J = 7.1 Hz), 3.10 (2H, t, J = 7.1 Hz); 13C
NMR: (125 MHz, CDCl3) 162.9, 159.1, 138.3, 137.7, 136.9, 129.8,
129.1, 128.7, 126.7, 120.6, 115.0, 114.6, 114.4, 68.8, 66.1, 35.9; νmax/
cm−1: 1714 (CO), 1610, 1588, 1559; HRMS (ESI)+: m/z calcd for
[C19H18N2O3 + Na]
+, 345.1210; observed, 345.1195.
Ethyl 1-(3-(3-(((1H-Pyrazole-4-carbonyl)oxy)methyl)-5-
methoxyphenyl)prop-2-yn-1-yl)-1H-pyrazole-4-carboxylate
(12). TFA (1 mL) was added to 3-(3-(4-(ethoxycarbonyl)-1H-pyrazol-
1-yl)prop-1-yn-1-yl)-5-methoxybenzyl 1-(tetrahydro-2H-pyran-2-yl)-
1H-pyrazole-4-carboxylate 46 (75 mg, 0.15 mmol). The reaction
mixture was stirred over 15 min, then diluted with NaHCO3 solution
(20 mL) at 0 °C, and extracted into DCM (3 × 20 mL). The combined
organic extracts were washed (brine), dried (MgSO4), and concen-
trated in vacuo. Puriﬁcation by ﬂash column chromatography (0−100%
ethyl acetate in petroleum ether) aﬀorded 12 (42 mg, 63% yield).
LCMS (ESI+): m/z 409.3 [M + H]+, (ESI−): m/z 407.2 [M − H]−, rt
1.89 min, >99%; 1H NMR: (500 MHz, CDCl3) 8.19 (1H, s), 8.10 (2H,
s), 7.95 (1H, d, J = 0.5 Hz), 7.15−7.11 (1H, m), 6.98−6.94 (2H, m),
5.24 (2H, s), 5.17 (2H, s), 4.31 (2H, q, J = 7.2 Hz), 3.81 (3H, s), 1.35
(3H, t, J = 7.2 Hz); 13C NMR: (125 MHz, CDCl3) 163.1, 162.8, 159.7,
141.7, 138.2, 137.0 (br), 132.4, 124.0, 123.0, 116.5, 115.8, 115.4, 114.8,
86.9, 81.0, 65.3, 60.5, 55.6, 43.0, 14.5; νmax/cm
−1: 3127, 2977, 1706
(CO), 1592, 1555; HRMS (ESI)+: m/z calcd for [C21H20N4O5 +
H]+, 409.1506; observed, 409.1519.
3-Methoxy-5-(pyrrolidin-1-yl)benzyl 1H-Pyrazole-4-carbox-
ylate (13). Pyrrolidine (0.110mL, 1.32mmol) and tert-butanol (2mL)
were added to a mixture of 3-bromo-5-methoxybenzyl 1-(tetrahydro-
2H-pyran-2-yl)-1H-pyrazole-4-carboxylate 44 (0.500 g, 1.10 mmol),
caesium carbonate (0.430 g, 1.32 mmol), RuPhos (26 mg, 0.055
mmol), and RuPhos Pd G1 methyl tert-butyl ether adduct (45 mg,
0.055 mmol). The reaction mixture was stirred at 85 °C over 15 h, then
diluted with ethyl acetate (25 mL), washed with water (15 mL) and
brine (15 mL), dried (MgSO4), and concentrated in vacuo. TFA (4
mL) was added to the crude residue, and the reaction mixture was
stirred over 30 min. The reaction mixture was diluted with ethyl acetate
(100 mL), washed with NaHCO3 solution (3 × 100 mL) and brine
(100 mL), dried (MgSO4), and concentrated in vacuo. Puriﬁcation by
reverse phase chromatography (0−45% acetonitrile in water (+0.1%
NH3)), followed by ﬂash column chromatography (0−4% methanol in
DCM), aﬀorded 13 (23 mg, 7% yield). LCMS (ESI+):m/z 302.2 [M +
H]+, (ESI−): m/z 300.1 [M −H]−, rt 1.91 min, >99%; 1H NMR: (500
MHz, CDCl3) 8.09 (2H, s), 6.31−6.28 (1H, m), 6.25−6.22 (1H, m),
6.07 (1H, t, J = 2.2 Hz), 5.22 (2H, s), 3.80 (3H, s), 3.31−3.25 (4H, m),
2.02−1.96 (4H,m); 13CNMR: (125MHz, CDCl3) 163.1, 161.0, 149.4,
138.0, 136.8, 115.1, 104.8, 100.7, 97.6, 66.9, 55.3, 47.8, 25.6; νmax/cm
−1:
3200 (br, N−H), 2962, 2840, 1712 (CO), 1586; HRMS (ESI)+:m/z
calcd for [C16H19N3O3 + H]
+, 302.1499; observed, 302.1500.
3-Methoxy-5-(pyridin-3-yl)benzyl 1H-Pyrazole-4-carboxy-
late (14). Dioxane (2 mL) and water (0.5 mL) were added to a
mixture of 3-bromo-5-methoxybenzyl 1-(tetrahydro-2H-pyran-2-yl)-
1H-pyrazole-4-carboxylate 44 (0.200 g, 0.435 mmol), 3-pyridinylbor-
onic acid (59mg, 0.479mmol), Pd(dppf)Cl2 (16mg, 0.022mmol), and
potassium carbonate (0.241 g, 1.74 mmol). The reaction mixture was
heated to 100 °C bymicrowave for 30 min, then diluted with DCM (25
mL), washed with NaHCO3 solution (3× 25mL), dried (MgSO4), and
concentrated in vacuo. TFA (2mL)was added to the crude residue, and
the reaction mixture was stirred over 15 min. The reaction mixture was
diluted with DCM (100 mL), washed with NaHCO3 solution (3 × 100
mL) and brine (100 mL), dried (MgSO4), and concentrated in vacuo.
Puriﬁcation by ﬂash column chromatography (75% ethyl acetate in
petroleum ether) aﬀorded 14 (59 mg, 44% yield). LCMS (ESI+): m/z
310.2 [M + H]+, (ESI−): m/z 308.1 [M − H]−, rt 1.45 min, >99%; 1H
NMR: (500 MHz, CD3OD) 8.79 (1H, dd, J = 2.3, 0.7 Hz), 8.52 (1H,
dd, J = 5.0, 1.5 Hz), 8.32−7.90 (2H, br s), 8.09 (1H, ddd, J = 8.0, 2.3, 1.6
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Hz), 7.52 (1H, ddd, J = 8.0, 4.9, 0.8 Hz), 7.31−7.27 (1H, m), 7.16 (1H,
t, J = 2.0Hz), 7.10−7.04 (1H, m), 5.34 (2H, s), 3.87 (3H, s); 13CNMR:
(125 MHz, CD3OD) 164.6, 162.1, 148.9, 148.3, 140.4, 140.3, 138.3,
136.8, 133.6 (br), 125.5, 120.1, 115.3, 114.6, 113.5, 66.7, 56.0; νmax/
cm−1: 3100 (br, N−H), 2940, 1708 (CO), 1598, 1562; HRMS
(ESI)+: m/z calcd for [C17H15N3O3 + H]
+, 310.1186; observed,
310.1186.
3-Methoxy-5-(pyridin-3-ylmethyl)benzyl-1H-pyrazole-4-
carboxylate (15). 1,2-Dimethoxyethane (4 mL) and water (1 mL)
were added to a mixture of 3-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)benzyl 1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-
4-carboxylate 47 (0.192 g, 0.347 mmol), 3-(bromomethyl)pyridine
hydrobromide (0.105 g, 0.417 mmol), tetrakis(triphenylphosphine)-
palladium(0) (40 mg, 0.035 mmol), and potassium carbonate (0.240 g,
1.74 mmol). The reaction mixture was heated to 95 °C over 10 h, then
diluted with water (15 mL), and extracted into DCM (3× 25 mL). The
combined organic extracts were washed (brine), dried (MgSO4), and
concentrated in vacuo. Puriﬁcation by ﬂash column chromatography
(0−100% ethyl acetate in petroleum ether) was attempted, and TFA
(0.5 mL) was added to the resultant residue. The reaction mixture was
stirred over 30 min, then diluted with NaHCO3 solution (15 mL), and
extracted into DCM (3 × 25 mL). The combined organic extracts were
washed with NaHCO3 solution (25 mL) and brine (25 mL), dried
(MgSO4), and concentrated in vacuo. Puriﬁcation by ﬂash column
chromatography (0−100% ethyl acetate in petroleum ether, 0−10%
methanol in DCM) aﬀorded 15 (20 mg, 18% yield).
LCMS (ESI+):m/z 324.2 [M+H]+, (ESI−):m/z 322.1 [M−H]−, rt
1.30min, 98%; 1HNMR: (500MHz, CDCl3) 8.51 (1H, s), 8.47 (1H, d,
J = 4.9 Hz), 8.06 (2H, s), 7.52−7.47 (1H, m), 7.22 (1H, dd, J = 7.8, 4.9
Hz), 6.84−6.79 (2H, m), 6.70−6.66 (1H, m), 5.23 (2H, s), 3.96 (2H,
s), 3.78 (3H, s); 13C NMR: (125 MHz, CDCl3) 162.9, 160.2, 150.2,
147.8, 141.8, 138.1, 136.9, 136.7, 136.3, 123.7, 120.9, 114.9, 114.6,
111.7, 65.9, 55.5, 39.1; νmax/cm
−1: 3150 (br, N−H), 2936, 1709 (C
O), 1597, 1562; HRMS (ESI)+: m/z calcd for [C18H17N3O3 + H]
+,
324.1343; observed, 324.1330.
5-(3-Methoxyphenyl)-1H-pyrazol-3-amine (19).25 Hydrazine
monohydrate (1.1 mL, 23 mmol) was added to a suspension of 3-(3-
methoxyphenyl)-3-oxopropanenitrile 49 (0.400 g, 2.28 mmol) in
ethanol (10 mL). The reaction mixture was heated under reﬂux for 6 h,
then quenched with excess acetone at room temperature, and
concentrated in vacuo. Puriﬁcation by ﬂash column chromatography
(0−50% ethyl acetate in petroleum ether, 0−6% methanol in DCM)
aﬀorded 19 (0.314 g, 73% yield). LCMS (ESI+): m/z 190.2 [M + H]+,
rt 1.21 min, >99%; 1H NMR: (500 MHz, CDCl3) 7.28 (1H, t, J = 8.0
Hz), 7.13 (1H, dt, J = 7.7, 1.2 Hz), 7.09 (1H, t, J = 2.0 Hz), 6.86 (1H,
ddd, J = 8.2, 2.6, 0.8 Hz), 5.89 (1H, s), 3.80 (3H, s); 13C NMR: (125
MHz, CDCl3) 160.1, 154.5, 145.7, 131.8, 130.1, 118.0, 114.0, 111.2,
90.7, 55.4; νmax/cm
−1: 3200 (br, N−H), 2837, 1612, 1589, 1567, 1506;
HRMS (ESI)+: m/z calcd for [C10H11N3O + H]
+, 190.0975; observed,
190.0972.
5-(1-(4-Methoxybenzyl)-1H-indol-6-yl)-1H-pyrazol-3-amine
(24a). Hydrazine monohydrate (42 μL, 0.67 mmol) was added to a
solution of 3-(1-(4-methoxybenzyl)-1H-indol-6-yl)-3-oxopropaneni-
trile 55a (0.200 g, 0.611 mmol) in ethanol (5 mL). The reaction
mixture was heated under reﬂux for 30 min, and then further hydrazine
monohydrate (0.114 mL, 1.83 mmol) was added at room temperature.
The reaction mixture was heated under reﬂux for 4 h, then quenched
with excess acetone at room temperature, and concentrated in vacuo.
Puriﬁcation by ﬂash column chromatography (0−10% methanol in
DCM) aﬀorded 24a (0.120 g, 62% yield). LCMS (ESI+):m/z 319.3 [M
+ H]+, rt 1.65 min, >99%; 1H NMR: (500 MHz, CDCl3) 7.63 (1H, d, J
= 8.3 Hz), 7.46 (1H, s), 7.30−7.25 (1H, m), 7.12 (1H, d, J = 3.1 Hz),
7.06−7.02 (2H, m), 6.83−6.78 (2H, m), 6.52 (1H, d, J = 3.0 Hz), 5.88
(1H, s), 5.22 (2H, s), 3.74 (3H, s); 13C NMR: (125 MHz, CDCl3)
159.3, 155.0, 146.7, 136.5, 129.5, 129.3, 129.1, 128.3, 123.8, 121.6,
117.7, 114.3, 106.8, 101.9, 90.5, 55.4, 49.7; νmax/cm
−1: 3150 (br, N−
H), 2927, 1610, 1585, 1510; HRMS (ESI+):m/z calcd for [C19H18N4O
+ H]+, 319.1553; observed, 319.1557.
5-(1-(3-Methoxybenzyl)-1H-indol-6-yl)-1H-pyrazol-3-amine
(24b).Hydrazine monohydrate (0.104 mL, 2.14 mmol) was added to a
solution of 3-(1-(3-methoxybenzyl)-1H-indol-6-yl)-3-oxopropaneni-
trile 55b (65 mg, 0.21 mmol) in ethanol (4 mL). The reaction mixture
was heated under reﬂux for 5 h and then concentrated in vacuo.
Puriﬁcation by ﬂash column chromatography (0−100% ethyl acetate in
petroleum ether, 0−10% methanol in DCM) was carried out, followed
by reverse phase chromatography [0−40% acetonitrile in water (+0.1%
formic acid)] with addition of NaHCO3 solution (10 mL) to the
combined fractions and extraction into DCM (3 × 25 mL). The
combined organic extracts were washed (brine), dried (MgSO4), and
concentrated in vacuo to aﬀord 24b (27 mg, 40% yield). LCMS (ESI+):
m/z 319.2 [M +H]+, rt 1.65 min, >99%; 1HNMR: (500MHz, CDCl3)
7.66 (1H, d, J = 8.3 Hz), 7.42 (1H, s), 7.29−7.25 (1H, m), 7.21 (1H, t, J
= 7.9 Hz), 7.17 (1H, d, J = 3.2 Hz), 6.80 (1H, dd, J = 8.2, 2.4 Hz), 6.69
(1H, d, J = 7.6 Hz), 6.66−6.63 (1H, m), 6.56 (1H, dd, J = 3.2, 0.7 Hz),
5.89 (1H, s), 5.30 (2H, s), 3.72 (3H, s); 13C NMR: (125MHz, CDCl3)
160.2, 155.2, 146.6, 138.9, 136.6, 130.1, 129.8, 129.2, 123.8, 121.7,
119.1, 117.7, 113.0, 112.8, 106.8, 102.1, 90.7, 55.3, 50.2; νmax/cm
−1:
3150 (br, N−H), 1585, 1505; HRMS (ESI+): m/z calcd for
[C19H18N4O + H]
+, 319.1553; observed, 319.1542.
5-(1-Benzyl-1H-indol-6-yl)-1H-pyrazol-3-amine (24c). Hydra-
zine monohydrate (0.271 mL, 5.58 mmol) was added to a solution of 3-
(1-benzyl-1H-indol-6-yl)-3-oxopropanenitrile 55c (0.170 g, 0.558
mmol) in ethanol (10 mL). The reaction mixture was heated under
reﬂux for 8 h, then quenched with excess acetone at room temperature,
and concentrated in vacuo. Puriﬁcation by ﬂash column chromatog-
raphy (0−10% methanol in DCM) aﬀorded 24c (50 mg, 31% yield).
LCMS (ESI+):m/z 289.3 [M +H]+, rt 1.65min, >99%; 1HNMR: (400
MHz, CD3OD) 7.63 (1H, s), 7.58 (1H, d, J = 8.3 Hz), 7.34 (1H, dd, J =
8.4, 1.5 Hz), 7.31−7.20 (4H, m), 7.16 (2H, d, J = 7.2Hz), 6.50 (1H, d, J
= 3.1 Hz), 5.90 (1H, s), 5.42 (2H, s); 13C NMR: (125 MHz, CD3OD)
155.6, 148.7, 139.5, 137.9, 130.7, 130.4, 129.7, 128.5, 127.9, 125.5,
122.0, 118.5, 107.7, 102.6, 90.2, 50.7; νmax/cm
−1: 2920, 2849, 1583,
1503; HRMS (ESI+): m/z calcd for [C18H16N4 + H]
+, 289.1448;
observed, 289.1446.
2-((6-(3-Amino-1H-pyrazol-5-yl)-1H-indol-1-yl)methyl)-
benzonitrile (24d). n-Butyllithium (1.6 M in hexanes, 4.09 mL, 6.54
mmol) was added dropwise at−78 °C to a mixture of acetonitrile (0.68
mL, 13 mmol) and toluene (5 mL). The reaction mixture was stirred at
−78 °C over 30 min. A solution of methyl 1-(2-cyanobenzyl)-1H-
indole-6-carboxylate 54d (0.380 g, 1.31 mmol) in toluene (5 mL) was
added dropwise at −78 °C over 30 min. The reaction mixture was
stirred at −78 °C over 1 h, and then aqueous HCl (1 M, 15 mL) was
added dropwise at 0 °C. The product was extracted into ethyl acetate (3
× 25 mL). The combined organic extracts were washed (brine), dried
(MgSO4), and concentrated in vacuo. Puriﬁcation by ﬂash column
chromatography (0−80% ethyl acetate in petroleum ether) was
attempted. Ethanol (20 mL) was added to the crude residue, followed
by hydrazine monohydrate (0.50 mL, 10 mmol). The reaction mixture
was heated under reﬂux for 5 h, then quenched with excess acetone at
room temperature, and concentrated in vacuo. Puriﬁcation by ﬂash
column chromatography (0−10%methanol in DCM) aﬀorded 24d (73
mg, 18% yield), with 14 mg subjected to further puriﬁcation by ﬂash
column chromatography (0−100% ethyl acetate in petroleum ether, 0−
5% methanol in DCM). LCMS (ESI+): m/z 314.3 [M + H]+, rt 1.58
min, 96%; 1H NMR: (400 MHz, CD3OD) 7.77 (1H, dd, J = 7.6, 1.1
Hz), 7.63 (1H, s), 7.61 (1H, d, J = 8.4Hz), 7.49 (1H, td, J = 7.7, 1.2Hz),
7.44−7.35 (2H, m), 7.34 (1H, d, J = 3.2 Hz), 6.90 (1H, d, J = 7.9 Hz),
6.56 (1H, d, J = 3.2 Hz), 5.92 (1H, s), 5.64 (2H, s); 13C NMR: (125
MHz, CD3OD) 155.5, 148.5, 142.9, 137.9, 134.6, 134.2, 130.8, 130.4,
129.4, 128.8, 126.0, 122.2, 118.8, 118.3, 112.0, 107.5, 103.3, 90.2 (1
peak missing); νmax/cm
−1: 3200 (br, N−H), 2225 (CN), 1585,
1505; HRMS (ESI+): m/z calcd for [C19H15N5 + H]
+, 314.1400;
observed, 314.1402.
2-((6-(3-Amino-1H-pyrazol-5-yl)-1H-indol-1-yl)methyl)-
benzamide (24e). A suspension of 2-((6-(3-amino-1H-pyrazol-5-yl)-
1H-indol-1-yl)methyl)benzonitrile 24d (50 mg, 0.16 mmol) in
aqueous NaOH (10 M, 4 mL) was heated under reﬂux for 7 h. The
reaction mixture was adjusted to pH 3 and extracted into DCM/
methanol (10:1, 3 × 75 mL). The combined organic extracts were
washed (brine), dried (MgSO4), and concentrated in vacuo.
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Puriﬁcation by reverse phase column chromatography (0−35%
acetonitrile in water) aﬀorded 24e (15 mg, 28% yield). LCMS
(ESI+):m/z 332.3 [M+H]+, (ESI−):m/z 330.1 [M−H]−, rt 1.47min,
>99%; 1H NMR: (500 MHz, CD3OD) 7.62−7.52 (3H, m), 7.37−7.24
(4H, m), 6.82−6.75 (1H, m), 6.51 (1H, d, J = 3.0 Hz), 5.90 (1H, s),
5.64 (2H, s); 13C NMR: (125 MHz, CD3OD) 174.6, 138.0, 137.7,
135.9, 131.6, 131.2, 130.3, 128.7, 128.5, 125.3 (br), 122.0, 118.5, 107.7,
102.7, 90.5 (br), 48.3 (3 peaks missing); νmax/cm
−1: 3200 (br), 1635
(CO), 1505; HRMS (ESI)+: m/z calcd for [C19H17N5O + H]+,
332.1506; observed, 332.1504.
3-Amino-5-(1H-indol-6-yl)-1H-pyrazole-4-carbonitrile (25).
Hydrazine monohydrate (0.163 mL, 3.36 mmol) was added to a
suspension of 3-amino-4,4,4-trichloro-2-(1H-indole-6-carbonyl)but-2-
enenitrile 53 (0.690 g, 2.10 mmol) in ethanol (10 mL). The reaction
mixture was heated under reﬂux for 22 h and then quenched with excess
acetone at room temperature and concentrated in vacuo. Puriﬁcation
by ﬂash column chromatography (0−100% ethyl acetate in petroleum
ether) aﬀorded 25 (0.113 g, 24% yield). LCMS (ESI+):m/z 224.2 [M+
H]+, (ESI−): m/z 222.1 [M −H]−, rt 1.50 min, >99%; 1H NMR: (400
MHz, CD3OD) 7.89 (1H, s), 7.63 (1H, d, J = 8.0 Hz), 7.45 (1H, d, J =
7.0 Hz), 7.33 (1H, d, J = 2.1 Hz), 6.50 (1H, d, J = 2.7 Hz); 13C NMR:
(125 MHz, CD3OD) 137.5, 130.6, 127.8, 121.7, 118.5, 116.9, 110.6,
102.6 (4 peaks missing); νmax/cm
−1: 3411 (N−H), 3200 (br, N−H),
2221 (CN), 1634, 1584, 1527; HRMS (ESI+): m/z calcd for
[C12H9N5 + H]
+, 224.0931; observed, 224.0935.
3-Amino-5-(1-Benzyl-1H-indol-6-yl)-1H-pyrazole-4-carboni-
trile (26c). Trichloroacetonitrile (0.168 mL, 1.67 mmol) was added to
a suspension of 3-(1-benzyl-1H-indol-6-yl)-3-oxopropanenitrile 55c
(0.170 g, 0.558 mmol) and sodium acetate (0.229 g, 2.79 mmol) in
ethanol (5 mL). The reaction mixture was stirred over 9 h, then
concentrated in vacuo, diluted with water (20 mL), and extracted into
DCM (3 × 25 mL). The combined organic extracts were washed
(brine), dried (MgSO4), and concentrated in vacuo. The crude residue
was dissolved in ethanol (10 mL), and hydrazine monohydrate (0.271
mL, 5.58 mmol) was added. The reaction mixture was heated under
reﬂux for 5 h, then quenched with excess acetone at room temperature,
and concentrated in vacuo. Puriﬁcation by ﬂash column chromatog-
raphy (0−100% ethyl acetate in petroleum ether) aﬀorded 26c (78 mg,
45% yield). LCMS (ESI+):m/z 314.2 [M +H]+, (ESI−):m/z 312.1 [M
−H]−, rt 1.84 min, 100%; 1H NMR: (500 MHz, CDCl3) 7.72 (1H, s),
7.67 (1H, d, J = 8.3 Hz), 7.41 (1H, dd, J = 8.2, 1.5 Hz), 7.29−7.19 (4H,
m), 7.13−7.08 (2H, m), 6.57 (1H, dd, J = 3.1, 0.8 Hz), 5.26 (2H, s),
4.12 (2H, br s); 13C NMR: (125 MHz, CDCl3) 157.0, 150.1, 136.9,
136.2, 130.8, 130.4, 129.0, 128.0, 127.1, 122.0, 120.8, 117.6, 115.3,
108.2, 102.3, 76.1, 50.4; νmax/cm
−1: 3200 (br, N−H), 2211 (CN),
1621, 1582, 1524, 1501; HRMS (ESI+): m/z calcd for [C19H15N5 +
H]+, 314.1400; observed, 314.1404.
3-Amino-5-(1-(pyridin-3-ylmethyl)-1H-indol-6-yl)-1H-pyra-
zole-4-carbonitrile (26g). Trichloroacetonitrile (0.647 mL, 6.45
mmol) was added to a suspension of 3-oxo-3-(1-(pyridin-3-ylmethyl)-
1H-indol-6-yl)propanenitrile 55g (0.592 g, 2.15 mmol) and sodium
acetate (0.882 g, 10.8 mmol) in ethanol (20 mL). The reaction mixture
was stirred over 13 h, then concentrated in vacuo, diluted with water
(20 mL), and extracted into DCM (3× 25mL). The combined organic
extracts were washed (brine), dried (MgSO4), and concentrated in
vacuo. The crude residue was dissolved in ethanol (20 mL), and
hydrazine monohydrate (1.1 mL, 22 mmol) was added. The reaction
mixture was heated under reﬂux for 21 h, then quenched with excess
acetone at room temperature, and concentrated in vacuo. Puriﬁcation
by ﬂash column chromatography (0−100% ethyl acetate in DCM, 5%
methanol in DCM) aﬀorded 26g (0.367 g, 54% yield). LCMS (ESI+):
m/z 315.2 [M +H]+, (ESI−):m/z 313.1 [M−H]−, rt 1.38 min, >99%;
1H NMR: (400 MHz, (CD3)2SO) 12.09 (1H, br s), 8.56 (1H, s), 8.46
(1H, dd, J = 4.7, 1.3 Hz), 7.90 (1H, s), 7.74−7.56 (3H, m), 7.50 (1H, d,
J = 8.2 Hz), 7.32 (1H, dd, J = 7.7, 4.8 Hz), 6.55 (1H, d, J = 2.8 Hz), 6.26
(2H, br s), 5.49 (2H, s); 13C NMR: (100 MHz, (CD3)2SO) 148.8,
148.5, 135.4, 135.0, 133.5, 130.6, 128.9, 123.7, 120.9, 117.5, 116.5,
107.4, 101.6, 46.8 (4 peaks missing); νmax/cm
−1: 3345 (N−H), 3100
(br, N−H), 2215 (CN), 1662, 1600, 1502; HRMS (ESI−): m/z
calcd for [C18H14N6 − H]−, 313.1207; observed, 313.1195.
3-Amino-5-(1-((2-hydroxypyridin-3-yl)methyl)-1H-indol-6-
yl)-1H-pyrazole-4-carbonitrile (26j). Lithium chloride (12 mg, 0.29
mmol) and p-toluenesulfonic acid monohydrate (55 mg, 0.29 mmol)
were added to a solution of 3-amino-5-(1-((2-methoxypyridin-3-
yl)methyl)-1H-indol-6-yl)-1H-pyrazole-4-carbonitrile 26h (20 mg,
0.058 mmol) in DMF (1 mL). The reaction mixture was heated to
120 °C over 25 min, then diluted with ethyl acetate (100 mL), washed
with water (3 × 100 mL) and brine (100 mL), dried (MgSO4), and
concentrated in vacuo. Puriﬁcation by ﬂash column chromatography
(50−100% ethyl acetate in petroleum ether, 0−10% methanol in
DCM) aﬀorded 26j (10 mg, 51% yield). LCMS (ESI+): m/z 331.2 [M
+ H]+, (ESI−):m/z 329.1 [M −H]−, rt 1.55 min, 97%; 1H NMR: (500
MHz, CD3OD) 7.82 (1H, s), 7.66 (1H, d, J = 8.1 Hz), 7.51 (1H, d, J =
7.5 Hz), 7.45 (1H, s), 7.32 (1H, dd, J = 6.5, 2.0 Hz), 7.08 (1H, d, J = 4.8
Hz), 6.55 (1H, d, J = 2.8 Hz), 6.25 (1H, t, J = 6.7 Hz), 5.28 (2H, s); 13C
NMR: (125 MHz, CD3OD) 164.1, 140.1, 137.4, 135.0, 132.1, 131.4,
129.6, 122.3, 119.0, 116.9, 109.0, 108.0, 102.7, 46.2 (4 peaks missing);
νmax/cm
−1: 3150 (br, N−H/O−H), 2925, 2207 (CN), 1647, 1611,
1564, 1529, 1501; HRMS (ESI+): m/z calcd for [C18H14N6O + Na]
+,
353.1121; observed, 353.1105.
3-Amino-5-(1-((6-hydroxypyridin-3-yl)methyl)-1H-indol-6-
yl)-1H-pyrazole-4-carbonitrile (26k). Lithium chloride (26 mg,
0.61 mmol) and p-toluenesulfonic acid monohydrate (0.116 g, 0.610
mmol) were added to a solution of 3-amino-5-(1-((6-methoxypyridin-
3-yl)methyl)-1H-indol-6-yl)-1H-pyrazole-4-carbonitrile 26i (42 mg,
0.12 mmol) in DMF (1 mL). The reaction mixture was heated to 120
°C over 25 min, then diluted with ethyl acetate (100 mL), washed with
water (3 × 100 mL) and brine (100 mL), dried (MgSO4), and
concentrated in vacuo. Puriﬁcation by ﬂash column chromatography
(50−100% ethyl acetate in petroleum ether, 0−12% methanol in
DCM) aﬀorded 26k (19 mg, 47% yield). LCMS (ESI+):m/z 331.2 [M
+ H]+, (ESI−): m/z 329.1 [M − H]−, rt 1.47 min, >99%; 1H NMR:
(500MHz, (CD3)2SO) 12.01 (1H, br s), 11.54 (1H, br s), 7.94 (1H, s),
7.73−7.29 (5H, m), 6.51 (1H, d, J = 2.4 Hz), 6.39 (1H, br s), 6.26 (1H,
d, J = 9.3 Hz), 5.15 (2H, s); 13C NMR: (125 MHz, (CD3)2SO) 161.9,
141.0, 135.3, 133.9, 130.3, 128.8, 125.6, 120.8, 120.3, 117.4, 116.6,
114.6, 107.5, 101.4, 45.7 (3 peaks missing); νmax/cm
−1: 3436, 3340,
3231, 2941, 2211 (CN), 1661, 1614, 1533; HRMS (ESI)+:m/z calcd
for [C18H14N6O + H]
+, 331.1302; observed, 331.1289.
3-Amino-5-(1-(pyridin-4-ylmethyl)-1H-indol-6-yl)-1H-pyra-
zole-4-carbonitrile (26l). Trichloroacetonitrile (0.309 mL, 3.08
mmol) was added to a suspension of 3-oxo-3-(1-(pyridin-4-ylmethyl)-
1H-indol-6-yl)propanenitrile 55l (0.283 g, 1.03 mmol) and sodium
acetate (0.422 g, 5.14 mmol) in ethanol (20 mL). The reaction mixture
was stirred over 13 h, then concentrated in vacuo, diluted with water
(20 mL), and extracted into DCM (4× 25 mL). The combined organic
extracts were washed (brine), dried (MgSO4), and concentrated in
vacuo. The crude residue was dissolved in ethanol (20 mL), and
hydrazine monohydrate (0.500 mL, 10.3 mmol) was added. The
reaction mixture was heated under reﬂux for 21 h, then quenched with
excess acetone at room temperature, and concentrated in vacuo.
Puriﬁcation by ﬂash column chromatography (0−100% ethyl acetate in
DCM, 8%methanol in DCM) aﬀorded 26l (0.183 g, 57% yield). LCMS
(ESI+):m/z 315.2 [M+H]+, (ESI−):m/z 313.1 [M−H]−, rt 1.35min,
>99%; 1H NMR: (500 MHz, CD3OD) 8.40−8.36 (2H, m), 7.73 (1H,
s), 7.66 (1H, d, J = 8.3 Hz), 7.53 (1H, dd, J = 8.2, 1.1 Hz), 7.37 (1H, d, J
= 3.2 Hz), 7.12−7.08 (2H, m), 6.58 (1H, dd, J = 3.2, 0.8 Hz), 5.43 (2H,
s); 13C NMR: (125 MHz, CD3OD) 157.8, 152.5, 150.3, 149.7, 137.4,
131.7, 131.3, 124.6, 123.3, 122.4, 119.2, 116.9, 108.8, 103.3, 73.9, 49.7;
νmax/cm
−1: 2204 (CN), 1605, 1554, 1500; HRMS (ESI+):m/z calcd
for [C18H14N6 + H]
+, 315.1353; observed, 315.1350.
3-Amino-5-(1-(quinolin-4-ylmethyl)-1H-indol-6-yl)-1H-pyra-
zole-4-carbonitrile (26m).Trichloroacetonitrile (92 μL, 0.91 mmol)
was added to a suspension of 3-oxo-3-(1-(quinolin-4-ylmethyl)-1H-
indol-6-yl)propanenitrile 55m (99 mg, 0.30 mmol) and sodium acetate
(0.125 g, 1.52 mmol) in ethanol (10 mL). The reaction mixture was
stirred over 36 h, then diluted with water (50 mL), and extracted into
DCM (3 × 50 mL). The combined organic extracts were washed
(brine), dried (MgSO4), and concentrated in vacuo. The crude residue
was dissolved in ethanol (10 mL), and hydrazine monohydrate (0.148
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mL, 3.04 mmol) was added. The reaction mixture was heated under
reﬂux for 6 h and then concentrated in vacuo. Puriﬁcation by ﬂash
column chromatography (50−100% ethyl acetate in petroleum ether)
aﬀorded 26m (45 mg, 41% yield). LCMS (ESI+):m/z 365.3 [M +H]+,
(ESI−):m/z 363.2 [M−H]−, rt 1.55 min, >99%; 1HNMR: (400MHz,
CD3OD) 8.61 (1H, d, J = 4.6 Hz), 8.23 (1H, d, J = 8.3 Hz), 8.07 (1H, d,
J = 8.6Hz), 7.81 (1H, t, J = 7.9Hz), 7.76−7.65 (3H,m), 7.57 (1H, d, J =
7.9 Hz), 7.41 (1H, s), 6.65 (1H, d, J = 2.9 Hz), 6.62 (1H, d, J = 4.6 Hz),
5.99 (2H, s); 13C NMR: (125 MHz, CD3OD) 151.2, 148.5, 146.2,
137.8, 131.6, 131.2, 129.9, 128.6, 127.3, 124.3, 122.4, 119.6, 119.5,
117.0, 108.8, 103.6, 47.7 (5 peaks missing); νmax/cm
−1: 3150 (br, N−
H), 2210 (CN), 1621, 1595, 1504; HRMS (ESI+): m/z calcd for
[C22H16N6 + Na]
+, 387.1329; observed, 387.1328.
3-Amino-5-(1-((1-methylpiperidin-2-yl)methyl)-1H-indol-6-
yl)-1H-pyrazole-4-carbonitrile (26n). Trichloroacetonitrile (42 μL,
0.42 mmol) was added to a suspension of 3-(1-((1-methylpiperidin-2-
yl)methyl)-1H-indol-6-yl)-3-oxopropanenitrile 55n (43 mg, 0.14
mmol) and sodium acetate (58 mg, 0.71 mmol) in ethanol (5 mL).
The reaction mixture was stirred over 18 h, then diluted with NaHCO3
solution (12.5 mL) and water (12.5 mL), and extracted into DCM (3×
25 mL). The combined organic extracts were washed (brine), dried
(MgSO4), and concentrated in vacuo. The crude residue was dissolved
in ethanol (5 mL), and hydrazine monohydrate (69 μL, 1.4 mmol) was
added. The reaction mixture was heated under reﬂux for 24 h and then
concentrated in vacuo. Puriﬁcation by ﬂash column chromatography
(50−100% ethyl acetate in petroleum ether, 0−16% methanol in
DCM) aﬀorded 26n (27 mg, 57% yield). LCMS (ESI+):m/z 335.3 [M
+ H]+, (ESI−): m/z 333.2 [M − H]−, rt 1.22 min, >99%; 1H NMR:
(500 MHz, CD3OD) 7.90 (1H, s), 7.64 (1H, d, J = 8.4 Hz), 7.50 (1H,
dd, J = 8.4, 0.9 Hz), 7.31 (1H, d, J = 3.2 Hz), 6.52 (1H, dd, J = 3.2, 0.6
Hz), 4.74 (1H, dd, J = 14.3, 4.7 Hz), 4.07 (1H, dd, J = 14.4, 9.5 Hz),
3.11−3.03 (1H, m), 2.97−2.87 (1H, m), 2.66 (3H, s), 2.51 (1H, td, J =
11.3, 3.4 Hz), 1.74−1.58 (3H, m), 1.41−1.18 (3H, m); 13CNMR: (125
MHz, CD3OD) 157.9 (br), 152.8 (br), 137.5, 131.8, 131.3, 124.4 (br),
122.4, 119.0, 117.2, 109.1, 102.9, 74.3 (br), 64.2, 57.7, 42.8, 29.5, 25.5,
23.7 (1 peak missing); νmax/cm
−1: 3150 (br, N−H), 2927, 2210 (C
N), 1623, 1589, 1525, 1503; HRMS (ESI+):m/z calcd for [C19H22N6 +
H]+, 335.1979; observed, 335.1971.
3-Amino-5-(1-((1-methylpiperidin-3-yl)methyl)-1H-indol-6-
yl)-1H-pyrazole-4-carbonitrile (26o). Trichloroacetonitrile (0.143
mL, 1.42 mmol) was added to a suspension of 3-(1-((1-methylpiper-
idin-3-yl)methyl)-1H-indol-6-yl)-3-oxopropanenitrile 55o (0.140 g,
0.474 mmol) and sodium acetate (0.194 g, 2.37 mmol) in ethanol (3
mL). The reaction mixture was stirred over 3 h 30 min, then diluted
withNaHCO3 solution (10mL), and extracted into DCM (3× 25mL).
The combined organic extracts were washed (brine), dried (MgSO4),
and concentrated in vacuo. The crude residue was dissolved in ethanol
(5 mL), and hydrazine monohydrate (0.231 mL, 4.74 mmol) was
added. The reaction mixture was heated under reﬂux for 15 h and then
concentrated in vacuo. Puriﬁcation by ﬂash column chromatography
(50−100% ethyl acetate in petroleum ether, 0−20% methanol in
DCM) was carried out, followed by reverse phase chromatography (0−
8% acetonitrile in water (+0.1% formic acid)) with addition of
NaHCO3 solution (40 mL) to the combined fractions and extraction
into DCM/methanol (9:1, 4 × 50 mL). The combined organic extracts
were washed (brine), dried (MgSO4), and concentrated in vacuo to
aﬀord 26o (61 mg, 38% yield). LCMS (ESI+): m/z 335.3 [M + H]+,
(ESI−):m/z 333.2 [M−H]−, rt 1.23 min, >99%; 1HNMR: (500MHz,
CDCl3) 7.78 (1H, s), 7.63 (1H, d, J = 8.3 Hz), 7.41 (1H, dd, J = 8.2, 1.4
Hz), 7.11 (1H, d, J = 3.2 Hz), 6.49 (1H, dd, J = 3.0, 0.6 Hz), 4.44 (2H,
br s), 4.05−3.91 (2H, m), 2.68 (1H, d, J = 9.6 Hz), 2.61 (1H, d, J = 10.4
Hz), 2.32−2.21 (1H, m), 2.17 (3H, s), 2.05−1.88 (1H, m), 1.77 (1H, t
J = 10.2 Hz), 1.69−1.45 (3H, m), 1.06−0.92 (1H, m); 13C NMR: (125
MHz, CDCl3) 157.1, 150.2, 136.2, 130.8, 130.1, 121.8, 121.1, 117.6,
115.7, 108.2, 101.7, 76.0, 59.4, 56.1, 50.4, 46.4, 37.0, 28.0, 24.5; νmax/
cm−1: 3200 (br, N−H), 2932, 2788, 2209 (CN), 1622, 1590, 1524,
1501; HRMS (ESI+): m/z calcd for [C19H22N6 + H]
+, 335.1979;
observed, 335.1983.
3-Amino-5-(3-chloro-1-(pyridin-3-ylmethyl)-1H-indol-6-yl)-
1H-pyrazole-4-carbonitrile (27g). N-Chlorosuccinimide (21 mg,
0.16 mmol) was added to a solution of 3-amino-5-(1-(pyridin-3-
ylmethyl)-1H-indol-6-yl)-1H-pyrazole-4-carbonitrile 26g (50 mg, 0.16
mmol) in DMF (1 mL). The reaction mixture was stirred over 6 h, and
then further N-chlorosuccinimide (7 mg, 0.05 mmol) was added. The
reaction mixture was stirred over 90 min, then diluted with ethyl acetate
(100 mL), washed with NaHCO3 solution (2 × 100 mL) and brine
(100 mL), dried (MgSO4), and concentrated in vacuo. Puriﬁcation by
ﬂash column chromatography (0−100% ethyl acetate in petroleum
ether, 0−7% methanol in DCM), followed by reverse phase column
chromatography (0−50% acetonitrile in water), aﬀorded 27g (35 mg,
63% yield). LCMS (ESI+):m/z 349.2 [M +H]+, (ESI−):m/z 347.1 [M
−H]−, rt 1.57 min, >99%; 1HNMR: (500MHz, (CD3)2SO) 8.60 (1H,
d, J = 1.8 Hz), 8.47 (1H, dd, J = 4.8, 1.6 Hz), 7.97 (1H, s), 7.88 (1H, s),
7.67 (1H, dt, J = 7.9, 1.9 Hz), 7.61 (1H, dd, J = 8.4, 1.3 Hz), 7.58 (1H, d,
J = 8.4 Hz), 7.33 (1H, ddd, J = 7.9, 4.7, 0.8 Hz), 6.22 (2H, br s), 5.48
(2H, s); 13C NMR: (125 MHz, (CD3)2SO) 155.7, 149.6, 149.0, 148.6,
135.1, 134.6, 133.0, 127.2, 126.0, 125.4, 123.8, 118.4, 118.0, 116.5,
108.0, 103.5, 70.8, 47.0; νmax/cm
−1: 3344 (N−H), 2218 (CN), 1623,
1586, 1525; HRMS (ESI)−: m/z calcd for [C18H13ClN6 − H]−,
347.0817; observed, 347.0804.
3-Amino-5-(1-(4-(piperidin-1-ylmethyl)benzyl)-1H-indol-6-
yl)-1H-pyrazole-4-carbonitrile (29b). Trichloroacetonitrile (0.138
mL, 1.37 mmol) was added to a suspension of 3-oxo-3-(1-(4-
(piperidin-1-ylmethyl)benzyl)-1H-indol-6-yl)propanenitrile 83b
(0.170 g, 0.458 mmol) and sodium acetate (0.188 g, 2.29 mmol) in
ethanol (5 mL). The reaction mixture was stirred over 44 h, then
diluted with NaHCO3 solution (10 mL) and water (10 mL), and
extracted into DCM (3 × 20 mL). The combined organic extracts were
washed (brine), dried (MgSO4), and concentrated in vacuo. The crude
residue was dissolved in ethanol (10 mL), and hydrazine monohydrate
(0.223 mL, 4.58 mmol) was added. The reaction mixture was heated
under reﬂux for 24 h, then concentrated in vacuo. Puriﬁcation by ﬂash
column chromatography (0−100% ethyl acetate in petroleum ether, 0−
15% methanol in DCM) was carried out, followed by reverse phase
chromatography (0−35% acetonitrile in water (+0.1% formic acid))
with adjustment of the combined fractions to pH 8 and extraction into
DCM/methanol (10:1, 3 × 50 mL). The combined organic extracts
were washed (brine), dried (MgSO4), and concentrated in vacuo to
aﬀord 29b (60 mg, 32% yield). LCMS (ESI+): m/z 411.3 [M + H]+, rt
1.44 min, >99%; 1H NMR: (500 MHz, CDCl3) 7.70 (1H, s), 7.63 (1H,
d, J = 8.2 Hz), 7.40 (1H, dd, J = 8.2, 1.4 Hz), 7.21 (2H, d, J = 8.1 Hz),
7.19 (1H, d, J = 3.1 Hz), 7.04 (2H, d, J = 7.9 Hz), 6.54 (1H, dd, J = 3.2,
0.6 Hz), 5.20 (2H, s), 4.33 (2H, br s), 3.42 (2H, s), 2.36 (4H, br s), 1.50
(4H, quin, J = 5.6 Hz), 1.42−1.33 (2H, m); 13C NMR: (125 MHz,
CDCl3) 156.8, 150.2, 137.4, 136.2, 136.0, 130.6, 130.21, 130.17, 127.1,
121.9, 121.4, 117.7, 115.7, 108.1, 102.2, 75.7, 63.3, 54.5, 50.1, 25.6,
24.2; νmax/cm
−1: 3200 (br, N−H), 2931, 2211 (CN), 1621, 1584,
1502; HRMS (ESI+): m/z calcd for [C25H26N6 + H]
+, 411.2292;
observed, 411.2287.
3-Amino-5-(1-(4-(morpholinomethyl)benzyl)-1H-indol-6-
yl)-1H-pyrazole-4-carbonitrile (29c). Trichloroacetonitrile (0.142
mL, 1.42 mmol) was added to a suspension of 3-(1-(4-
(morpholinomethyl)benzyl)-1H-indol-6-yl)-3-oxopropanenitrile 83c
(0.190 g, 0.473 mmol) and sodium acetate (0.194 g, 2.37 mmol) in
ethanol (5 mL). The reaction mixture was stirred over 14 h, then
diluted with NaHCO3 solution (15 mL), and extracted into DCM (3 ×
25 mL). The combined organic extracts were washed (brine), dried
(MgSO4), and concentrated in vacuo. The crude residue was dissolved
in ethanol (5 mL), and hydrazine monohydrate (0.230 mL, 4.73 mmol)
was added. The reaction mixture was heated under reﬂux for 22 h and
then concentrated in vacuo. Puriﬁcation by ﬂash column chromatog-
raphy (0−100% ethyl acetate in petroleum ether, 0−10% methanol in
DCM) was carried out, followed by reverse phase chromatography
(100% water (+0.1% formic acid)) with adjustment of the combined
fractions to pH 8 and extraction into DCM/methanol (10:1, 3 × 50
mL). The combined organic extracts were washed (brine), dried
(MgSO4), and concentrated in vacuo to aﬀord 29c (81 mg, 42% yield).
LCMS (ESI+):m/z 413.3 [M +H]+, rt 1.36min, >99%; 1HNMR: (500
MHz, CDCl3) 7.73 (1H, s), 7.66 (1H, d, J = 8.2 Hz), 7.39 (1H, dd, J =
8.3, 1.3 Hz), 7.25−7.20 (3H, m), 7.08 (2H, d, J = 8.1 Hz), 6.56 (1H, dd,
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J = 3.2, 0.6 Hz), 5.26 (2H, s), 4.20 (2H, s), 3.64 (4H, t, J = 4.6 Hz), 3.41
(2H, s), 2.47−2.31 (4H, m); 13C NMR: (125 MHz, CDCl3) 157.0,
150.1, 137.6, 136.2, 135.9, 130.7, 130.4, 129.9, 127.1, 122.0, 121.0,
117.6, 115.4, 108.2, 102.3, 76.1, 67.0, 63.1, 53.7, 50.2; νmax/cm
−1: 3200
(br, N−H), 2922, 2212 (CN), 1740, 1624, 1584, 1502; HRMS
(ESI+): m/z calcd for [C24H24N6O + H]
+, 413.2084; observed,
413.2079.
3-Amino-5-(1-(4-((4-isopropylpiperazin-1-yl)methyl)-
benzyl)-1H-indol-6-yl)-1H-pyrazole-4-carbonitrile (29e). Tri-
chloroacetonitrile (0.129 mL, 1.29 mmol) was added to a suspension
of 3-(1-(4-((4-isopropylpiperazin-1-yl)methyl)benzyl)-1H-indol-6-
yl)-3-oxopropanenitrile 83e (0.178 g, 0.429 mmol) and sodium acetate
(0.176 g, 2.15 mmol) in ethanol (5 mL). The reaction mixture was
stirred over 10 h, then diluted with NaHCO3 solution (7.5 mL) and
water (7.5 mL), and extracted into DCM (3 × 25 mL). The combined
organic extracts were washed (brine), dried (MgSO4), and concen-
trated in vacuo. The crude residue was dissolved in ethanol (3 mL), and
hydrazine monohydrate (0.209 mL, 4.29 mmol) was added. The
reaction mixture was heated under reﬂux for 7 h, then quenched with
excess acetone at room temperature, and concentrated in vacuo.
Puriﬁcation by ﬂash column chromatography (50−100% ethyl acetate
in petroleum ether, 0−20% methanol in DCM (+0.1% NH3)) aﬀorded
29e (0.147 g, 75% yield). LCMS (ESI+): m/z 454.3 [M + H]+, (ESI−):
m/z 452.3 [M − H]−, rt 1.40 min, >99%; 1H NMR: (500 MHz,
CD3OD) 7.81 (1H, s), 7.63 (1H, d, J = 8.3Hz), 7.48 (1H, d, J = 8.1Hz),
7.39 (1H, d, J = 2.6 Hz), 7.25 (2H, d, J = 8.1 Hz), 7.21 (2H, d, J = 8.2
Hz), 6.53 (1H, d, J = 3.2 Hz), 5.36 (2H, s), 3.55 (2H, s), 3.36−3.29
(1H, m), 3.10 (4H, br s), 2.69 (4H, br s), 1.27 (6H, d, J = 6.9 Hz); 13C
NMR: (125 MHz, CD3OD) 138.6, 137.3, 137.1, 131.6, 131.4, 130.8,
128.5, 122.2, 118.7, 117.0, 109.2, 102.7, 62.3, 59.0, 51.0, 50.8, 49.4, 17.3
(4 peaksmissing); νmax/cm
−1: 2210 (CN), 1623, 1587, 1501; HRMS
(ESI)+:m/z calcd for [C27H31N7 + H]
+, 454.2714; observed, 454.2715.
4-Methyl-5-(1-(4-(pyrrolidin-1-ylmethyl)benzyl)-1H-indol-6-
yl)-1H-pyrazol-3-amine (30a). Hydrazine monohydrate (0.147 mL,
3.01 mmol) was added to a solution of 2-methyl-3-oxo-3-(1-(4-
(pyrrolidin-1-ylmethyl)benzyl)-1H-indol-6-yl)propanenitrile 84a
(0.140 g, 0.301 mmol) in ethanol (5 mL). The reaction mixture was
heated under reﬂux for 28 h, then quenched with excess acetone at
room temperature, and concentrated in vacuo. Puriﬁcation by ﬂash
column chromatography [50−100% ethyl acetate in petroleum ether,
0−20% methanol (+0.1% NH3) in DCM] aﬀorded 30a (24 mg, 21%
yield). LCMS (ESI+): m/z 386.3 [M + H]+, rt 1.25 min, >99%; 1H
NMR: (500 MHz, CDCl3) 7.69 (1H, d, J = 8.2 Hz), 7.30 (1H, s), 7.26
(2H, d, J = 8.1 Hz), 7.20 (1H, d, J = 3.2 Hz), 7.18 (1H, dd, J = 8.4, 1.5
Hz), 7.08 (2H, d, J = 8.1 Hz), 6.57 (1H, dd, J = 3.1, 0.7 Hz), 5.31 (2H,
s), 3.58 (2H, s), 2.53−2.43 (4H, m), 1.98 (3H, s), 1.81−1.71 (4H, m);
13C NMR: (125 MHz, CDCl3) 154.4, 142.7, 139.1, 136.4, 135.8, 129.7,
129.6, 128.8, 126.9, 124.3, 121.5, 119.0, 108.8, 101.9, 99.3, 60.3, 54.2,
50.3, 23.5, 7.9; νmax/cm
−1: 3200 (br, N−H), 2916, 2788, 1606, 1502;
HRMS (ESI)+: m/z calcd for [C24H27N5 + H]
+, 386.2339; observed,
386.2354.
5-(1-(4-(Piperidin-1-ylmethyl)benzyl)-1H-indol-6-yl)-1H-pyr-
azol-3-amine (31b).Hydrazinemonohydrate (0.136mL, 2.80mmol)
was added to a solution of 3-oxo-3-(1-(4-(piperidin-1-ylmethyl)-
benzyl)-1H-indol-6-yl)propanenitrile 83b (0.104 g, 0.280 mmol) in
ethanol (5 mL). The reaction mixture was heated under reﬂux for 21 h
and then concentrated in vacuo. Puriﬁcation by ﬂash column
chromatography (0−100% ethyl acetate in petroleum ether, 0−15%
methanol in DCM) was carried out, followed by reverse phase
chromatography [0−20% acetonitrile in water (+0.1% formic acid)]
with adjustment of the combined fractions to pH 14 and extraction into
DCM (3 × 25 mL). The combined organic extracts were washed
(brine), dried (MgSO4), and concentrated in vacuo to aﬀord 31b (56
mg, 52%). LCMS (ESI+): m/z 386.3 [M + H]+, rt 1.24 min, >99%; 1H
NMR: (500MHz, CDCl3) 7.64 (1H, d, J = 8.3 Hz), 7.44 (1H, s), 7.30−
7.25 (1H, m), 7.23 (2H, d, J = 8.1 Hz), 7.14 (1H, d, J = 3.2 Hz), 7.03
(2H, d, J = 8.2 Hz), 6.54 (1H, dd, J = 3.1, 0.7 Hz), 5.88 (1H, s), 5.27
(2H, s), 3.68 (2H, br s), 3.41 (2H, s), 2.33 (4H, br s), 1.58−1.50 (4H,
m), 1.45−1.36 (2H, m); 13C NMR: (125 MHz, CDCl3) 155.1 (br),
146.6 (br), 138.4, 136.6, 135.8, 129.8, 129.7, 129.1, 126.7, 123.9, 121.6,
117.7, 106.8, 102.0, 90.6, 63.5, 54.6, 50.0, 26.0, 24.4; νmax/cm
−1: 2926,
2848, 2789, 2757, 1586, 1505; HRMS (ESI+):m/z calcd for [C24H27N5
+ H]+, 386.2339; observed, 386.2336.
Expression and Puriﬁcation of Full Length Mab TrmD.
Expression and puriﬁcation was carried out as previously described.12
AVA0421 plasmid with an N-His-3C Protease site-TrmD full-length
insert (kindly provided by the Seattle Structural Genomics Con-
sortium) was used for expression. E. coli BL21 (DE3) strain containing
the above plasmid was grown overnight at 37 °C in 2xYT media,
supplemented with ampicillin (100 μg/mL), until optical density
(A600nm) reached 0.6. The expression of recombinant construct was
induced by the addition of isopropyl β-D-1-thiogalactopyranoside
(IPTG) to a ﬁnal concentration of 0.5 mM and further allowed to grow
at 18 °C for 16 h. Cells were harvested by centrifugation at 4 °C for 20
min at 5000g and the pellet re-suspended in buﬀer A [25 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.5, 500
mM NaCl, 5% glycerol, 10 mM MgCl2, 1 mM tris(2-carboxyethyl)-
phosphine (TCEP), 20 mM imidazole]. 0.1% Triton (Sigma), 10 μg/
mL DNaseI, 5 mM MgCl2, and 3 protease inhibitor cocktail tablets
(New England Biolabs) were added to the cell suspension. The clariﬁed
cell lysate was ﬁltered using a 0.45 μm syringe ﬁlter and passed through
a pre-equilibrated (with buﬀer A), 10 mL pre-packed nickel-sepharose
column (HiTrap IMAC FF, GE Healthcare). The column was washed
with buﬀer A and the bound protein eluted using buﬀer B (25 mM
HEPES pH 7.5, 500 mM NaCl, 5% glycerol, 1 mM TCEP, 500 mM
imidazole). 3C Protease was added to the pooled elutes and subjected
to dialysis, against 2 L of buﬀer C (25 mM HEPES pH 7.5, 500 mM
NaCl, 5% glycerol, 1 mM TCEP) overnight at 4 °C, to cleave the His-
tag. The dialyzed protein was then passed through a pre-equilibrated
(buﬀer A) 5 mL HiTrap IMAC FF Nickel column (GE Healthcare).
The ﬂow through from the column was collected and concentrated to 3
mL using a 10 kDa centrifugal concentrator (Sartorius Stedim) and
loaded onto a pre-equilibrated (with buﬀer D: 25 mM HEPES pH 7.5,
500mMNaCl, 5% glycerol) 120mL Superdex200 16/600 column (GE
Healthcare), and 2 mL fractions were collected and analyzed on a 15%
SDS-PAGE gel and by MALDI ﬁngerprinting.
Soaking andCo-crystallization ofMab TrmDwith Fragments
and Compounds. Experiments for SAM, 1, 16, 20, 23, 24f, 26f, 29a,
29d, and 31a have been described.12 Soaking experiments with the
remaining compounds were performed as previously described.12 Mab
TrmD apo crystals were grown at 19 °C in 48-well sitting drop plates
(Swiss CDI) using 0.08 mM sodium cacodylate pH 6.5−7.0, 1−2 M
ammonium sulfate and 20 mg/mL of the protein in storage buﬀer (25
mM HEPES pH 7.5, 500 mM NaCl, 5% glycerol) at drop ratio 1 μL/1
μL (protein: reservoir respectively) and equilibrated against 250 μL
reservoir solution. The apo crystals formed were allowed to soak in a 4
μL drop containing reservoir solution and 10 mM compound (in
DMSO) and equilibrated against 700 μL of the corresponding reservoir
solution overnight at 19 °C in 24-well hanging drop vapor diﬀusion
plates.
X-ray Data Collection and Processing. TheMab TrmD crystals
were cryo-cooled in mother liquor containing 27.5% ethylene glycol.
Crystallographic data collection and processing was performed as
previously described.12 X-ray data sets were collected on I04, I03, I02,
I04-1, or I24 beamlines at the Diamond Light Source (UK), using the
rotation method at a wavelength of 0.979 Å, omega start: 0°, omega
oscillation: 0.1°−0.2°, total images: 2100−2400, exposure time: 0.05−
0.08 s. The diﬀraction images were processed using AutoPROC,
utilizing XDS for indexing, integration, followed by POINTLESS,
AIMLESS and TRUNCATE programs from CCP4 Suite for data
reduction, scaling, and the calculation of structure factor amplitudes
and intensity statistics.33−38
Mab TrmD ligand-bound structures were solved by molecular
replacement using PHASER with the atomic coordinates of the solved
Mab TrmD apo structure (PDB code 6NVR) as a search model.39
Structure reﬁnement was carried out using REFMAC and PHE-
NIX.40,41 Themodels obtained weremanually re-built using the COOT
interactive graphics program and electron density maps calculated with
2|Fo|− |Fc| and |Fo|− |Fc| coeﬃcients.
42,43 Positions of ligands and water
molecules were located in diﬀerence electron density maps, and OMIT
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.9b00809
J. Med. Chem. XXXX, XXX, XXX−XXX
T
diﬀerence maps |mFo − DFc| were calculated and analyzed to further
verify positions of ligands.44
Diﬀerential Scanning Fluorimetry. Experiments for fragments 1,
16−18, and 20−21 at 5 mM concentration have been described.12 DSF
was performed using a BioRad CFX Connect system, from 25 to 95 °C
in 0.5 °C increments of 30 s duration. Samples were run in 96-well
plates, with each well containing a ﬁnal volume of 25 μL. Screening was
conducted with 50 mM HEPES pH 7.5, 500 mM NaCl, 5x
SyproOrange, 10 μM Mab TrmD, and either 5% DMSO or 5% ligand
stock solution in DMSO.
Isothermal Titration Calorimetry. Experiments for 16, 20, 23,
24f, 26f, 28, 29a, 29d, and 31a have been described.12 ITC experiments
with the remaining compounds to quantify binding toMab TrmD were
performed as previously described,12 using Malvern MicroCal iTC200
or Auto-iTC200 systems at 25 °C. Titrations consisted of an initial
injection (0.2 μL), discarded during data processing, followed by either
19 (2 μL) or 39 (1 μL) injections separated by intervals of 60−150 s
duration. Protein was dialyzed overnight at 4 °C in storage buﬀer (50
mM HEPES pH 7.5, 500 mM NaCl, 5% glycerol). Sample cell and
syringe solutions were prepared using the same storage buﬀer, with a
ﬁnal DMSO concentration of 2−10% according to ligand solubility in
the buﬀer. TrmD concentrations of either 33 or 100 μMwere used, with
ligand to protein concentration ratios ranging from 10 to 20:1. Control
titrations without protein were also performed and subtracted from
ligand to protein titrations. Titrations were ﬁtted with Origin software
(OriginLab, Northampton, MA, USA), using a one-site binding model
with N ﬁxed to 1 only for weakly binding ligands. Titrations were
typically performed once (n = 1), withmultiple isotherms obtained (n >
1) for key compounds of interest. Kd values are reported to 2 signiﬁcant
ﬁgures. Error provided by Origin software due to model ﬁt is reported
when n = 1, whereas standard deviation is reported when n > 1.
For the reverse ITC titration with 26o (Figure S8b), protein solution
(420 μM TrmD) was injected into the sample cell (35 μM ligand).
Other aspects of the experiment setup and analysis were identical to the
forward titrations.
Native Mass Spectrometry. Native nanoelectrospray ionization
mass spectrometry spectra were recorded on a Synapt HDMS mass
spectrometer (Waters, Manchester, UK) modiﬁed for studying high
masses. Mab TrmD was exchanged into 200 mM ammonium acetate
(pH 7.0) solution using Micro Bio-Spin 6 chromatography columns
(Bio-Rad, UK). Protein samples were equilibrated at room temperature
in the absence or presence of the indicated concentrations of ligands for
at least 15 min before analysis. Protein solution (2.5 μL) was injected
into a gold-coated borosilicate emitter (Thermo Scientiﬁc, UK) for
sampling. Typical conditions were capillary voltage 1.5 kV, cone voltage
50 V, trap collision voltage 20 V, transfer collision voltage 20 V, source
temperature 20 °C, backing pressure 3−4 mbar, trap pressure 3−4 ×
10−2 mbar, IM (N2) pressure 5−6 × 10−1 mbar and TOF pressure 7−8
× 10−7 mbar. All mass spectra were calibrated externally with caesium
iodide (10 mg/mL). Data acquisition and processing were performed
using MassLynx 4.1 (Waters).
Screening againstMab.Mab subspecies abscessus (ATCC 19977)
was transformed with pmv310 plasmid expressing Lux ABDCE operon,
grown in Middlebrook 7H9 broth supplemented with ADC (Sigma,
UK). Minimum Inhibitory Concentrations (MIC) were determined
according to the Clinical and Laboratory Standards Institute (CLSI)
methodM07-A9. Mycobacteria were grown to an OD600 of 0.2−0.3 in
liquid culture, and 1 × 105 bacteria were added to each well of 96-well
plates containing serial dilutions of compound (400, 200, 100, 50, 25,
12.5, 6.3, 3.1, 1.6, 0.8, 0.4, 0 μM), in triplicate wells per condition, and
incubated at 37 °C until growth was seen in the control wells. The MIC
value was determined as the last well which showed no bacterial growth.
Screening against H37Rv Mtb. Antimicrobial susceptibility
testing against Mtb H37Rv was performed in various media including:
GAST-Fe, 7H9/ADC, 7H9/DPPC (4.7 g/L 7H9 base, 14 mg/L
DPPC, 0.81 g/L NaCl, 0.3 g/L Casitone, and 0.05% Tyloxapol), and
7H9/Glucose (4.7 g/L 7H9 base, 4 g/L glucose, 0.81 g/LNaCl, 0.3 g/L
Casitone, and 0.05% Tyloxapol). H37Rv was grown in the
corresponding media to OD 0.2−0.4 prior to use. A two-fold serial
dilution series (50 μL) was placed in each well of a sterile 96-well round
bottom plate, and then 50 μL of H37Rv diluted to OD 0.0002 was
added. Plates were incubated at 37 °C for 2 weeks prior to determining
MIC. The MIC is deﬁned here as the drug concentration that
completely inhibits growth of cells.
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W.; Echols, N.; Headd, J. J.; Hung, L.-W.; Kapral, G. J.; Grosse-
Kunstleve, R. W.; McCoy, A. J.; Moriarty, N. W.; Oeffner, R.; Read, R.
J.; Richardson, D. C.; Richardson, J. S.; Terwilliger, T. C.; Zwart, P. H.
PHENIX: A comprehensive Python-based system for macromolecular
structure solution. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66,
213−221.
(42) Emsley, P.; Cowtan, K. Coot: Model-building tools for molecular
graphics. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 2126−
2132.
(43) Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Features and
development ofCoot. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010,
66, 486−501.
(44) Hodel, A.; Kim, S. H.; Brünger, A. T. Model bias in
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